


nContact  
A BRAND OF

.....

AtriCure®



# Epi-Sense® Guided Coagulation System Instructions for Use

2025-03 | IFU-0020.E

**Rx ONLY**

⚠ **CAUTION:** Federal law (US) restricts this device to sale by or on the order of a physician.



AtriCure Inc.  
7555 Innovation Way  
Mason, Ohio 45040 USA  
+1 866 349 2342  
+1 513 755 4100

**DEVICE SETUP**

**Device Description**

Components of the Guided Coagulation System:

- One (1) **CDK-1413** 3cm Epi-Sense Guided Coagulation System Device (STERILE in unopened, undamaged package. For single use only. Do not re-sterilize. Do not re-use.)

**PROVIDED SEPARATELY BY ATRICURE:**

- Compatible AtriCure RF Generator (CS-3000 or MAG) plus accessories, Non-Sterile, Reusable (under separate IFU)
- CSK-2030** nContact Sensing Cable, Non-Sterile, Reusable (under separate IFU)
- CSK-2000** nContact RF Cable, Sterile, Single Use (under separate IFU)
- CSK-6130 or CSK-6131** – nContact Cannula– Sterile, Single Use (under separate IFU)


**COMPONENTS REQUIRED FOR USE BUT NOT OFFERED BY ATRICURE:**

- Indifferent patient return electrode - surface area of 21 square inches (136 cm<sup>2</sup>) minimum

The Epi-Sense Guided Coagulation Device is not made with natural rubber latex and does not contain PVC or phthalates.


**Product Features**

FIG. 1. GENERAL COAGULATION DEVICE KEY FEATURES




- Handle;
- Vacuum Port
- Guide Wire Exit Port;
- RF Connection;
- Perfusion Port;
- Stopcock;
- Graduated Fitting to Vacuum Tubing;
- Strain Relief;
- Main Body;
- Distal Shell;
- Coagulation Electrode and Sensing Electrodes;
- Guide Tube Opening;
- Insulative Covering;
- Vacuum Lumen;
- Locator Arrows (1cm [0.4"] spacing)

FIG 2.A NCONTACT GENERATOR KEY FEATURES



- CSK-2030 Cable Connection;
- Indifferent, Dispersive Electrode Connection;
- Footswitch Connection;
- Diagnostic Device Connection;
- Power Adjustment;
- Time Adjustments;
- Mode button;
- RF ON/OFF Button;
- Standby Mode LED;
- Error LED;
- RF LED

FIG 2.B MAG GENERATOR KEY FEATURES



- Sense-Pace Input (MLP);
- Pens Receptacle;
- Clamp Receptacle;
- Epi-Sense Receptacle;
- Return Electrode Receptacle

**Indications for Use:**

The Epi-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients:

- who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and,
- in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions.

**Contraindications:**

The Epi-Sense Guided Coagulation System is contraindicated for use in:

- Patients with presence of left atrial thrombus, a systemic infection, active endocarditis, or another infection local to the surgical site at the time of surgery.
- Patients with Barrett's Esophagitis.

**Environmental Specifications**

	Temperature	Humidity	Atmospheric Pressure
Operational	10 to 40°C (50 to 104°F)	30%-75% relative humidity non-condensing	700 to 1060 millibar (10 to 15 psi)
Transit	-29 to 55°C (-20 to 131°F)	30-85% relative humidity	N/A
Storage	-29 to 55°C (-20 to 131°F)	30-85% relative humidity	N/A

**⚠️ WARNINGS ⚠️**

Physicians should consider post-operative anti-inflammatory medication to decrease the potential for post-operative pericarditis and/or delayed post-procedure inflammatory pericardial effusions

Physicians should obtain post-procedural imaging (i.e. 1-3 weeks post-procedure) for detection of post-procedure inflammatory pericardial effusions.

### **⚠️ WARNINGS ⚠️**

The coagulation device utilizes preset power and time settings; adjustment of these settings may result in excess or inadequate energy transmission.

Physicians should consider post-operative proton pump inhibitors (PPIs) to decrease the potential for post-operative esophageal irritations.

The EPI-Sense Guided Coagulation System should only be used under direct visualization. Care should be taken to visualize the devices and/or guidewire components when in the body, during introduction and/or removal from the Cannula. Always fully retract devices and components prior to insertion and removal in order to avoid inadvertent tissue damage with the devices and or guidewire.

When inserting or retracting Cannula from body, ablation device and standard 0.035" or 0.038" guidewire should NOT be extended beyond tip of Cannula.

Excessive flexing and/or improper manipulation of the EPI-Sense with surgical tools can result in damage to the device.

Care should be taken to ensure that the device is not in contact with tissue that is not going to be coagulated (e.g. vascular and nerve tissue), in order to avoid inadvertent tissue damage.

To avoid unintentional coagulation, always ensure the device or device combined with optional guidewire is oriented toward the desired coagulation location.

Avoid contact with other surgical instruments, scopes, staples, or other objects while coagulating. Inadvertent contact with objects while coagulating could lead to conduction of RF energy or heat and unintentional coagulation of tissues in contact with those objects.

The device is provided sterile and is intended for single patient use only. Do not reprocess or reuse. Reuse can cause damage to device, patient injury, and/or the communication of infectious disease(s) from one patient to another.

Do not scrape or scratch off the gold surface of the sensing electrodes when cleaning the RF coagulation electrode to avoid an adverse reaction due to copper or nickel exposure to the patient.

To avoid unintentional coagulation, care should be taken to ensure overlapping structures are separated and thermally isolated when anatomy allows.

Inspect all devices and packaging prior to use. If any breach of the packaging is found the sterility of the product cannot be ensured which poses a risk of patient injury. Do not use product if breach is found.

The risk of igniting flammable gases or other materials is inherent in the application of RF energy. Precautions must be taken to restrict flammable materials from the area where tissue coagulation is performed.

Care should be taken to ensure device is not moved during RF power delivery. Device movement may cause loss of suction and tissue tear and/or unintentional ablation.

Ensure overlapping structures are separated and thermally isolated when anatomy allows. If the overlapping structures cannot be separated and thermally isolated, ablation should not be performed.

Care should be taken to ensure no vessels (or other structures) are restricted during device manipulation. Vessel restriction could cause hemodynamic instabilities or patient harm.

Care should be taken to confirm device placement before power application to avoid collateral tissue damage.

Care should be taken to fill distal end of Cannula with room temperature saline during ablation to avoid collateral tissue damage.

Care should be taken to ensure device is perfused during ablation to avoid unintentional tissue damage.

Physicians should implement a comprehensive anti-coagulation protocol including pre-operative, intra-operative and post-operative anticoagulation management to prevent potential thromboemboli.

### **⚠️ WARNINGS ⚠️**

Physicians should use esophageal temperature monitoring as was conducted during the clinical investigation of the device to monitor for potential collateral tissue damage. Throughout the procedure ensure the probe is located directly behind the ablation probe to ensure an accurate reading.

Reuse of the ground pad utilized in the epicardial portion of the procedure for the endocardial portion may result in patient harm.

The coils on the distal end of the device must be kept clean of coagulum during surgery to avoid loss of power. Do not clean coagulum off the electrode of the device with an abrasive cleaner or electrosurgical tip cleaner. The electrodes could be damaged resulting in device failure.

The coagulation devices should be used by physicians trained in the techniques of minimally invasive endoscopic surgical procedures and in the specific approach to be used to prevent patient harm.

If using a TEE probe, care should be taken to withdraw the TEE probe prior to ablation to avoid compressing the esophagus against the left atrium during ablation.

If the coagulation device is used near a pacemaker/AICD, a potential hazard exists due to possible interference with the action of the pacemaker and potential damage to the pacemaker. Consider placing a magnet on the pacemaker/AICD or programming the pacemaker/AICD per the manufacturer's instructions for use before applying RF energy.

Care should be taken to ensure device is not twisted or over manipulated during procedure. Twisting/torqueing/over manipulating device can cause damage to the device, the lumen to collapse, fracture of electrodes or vacuum lumen spring, separation of electrodes from device, kinking of PEEK guide tube, loss of suction, disconnection of perfusion/IV tubing, kinked perfusion/IV tubing, or patient harm.

Care should be taken to assure the ablation electrode is oriented towards the heart and away from the pericardium using visual cues, i.e. Reference Dots, Locator Arrows, and black stripe.

Connection of multiple devices to one vacuum unit may reduce vacuum functionality.

Care should be taken to ensure optional guidewire stays on the sterile field during manipulation to prevent infection.

Before coagulation of tissue, ensure guidewire and/or scope are not between tissue and coagulation device electrode.

If a guidewire is used with guided device, ensure that insulative covering is intact along the exposed Guidewire to prevent ablation of unintended tissue.

Care should be taken to ensure the path to position the device is large enough to advance the device easily – forcing the device may damage the device, cause tissue damage or patient harm.

While the distal portion of the device is designed to be malleable to conform to the anatomy of the area to be coagulated, excessive manipulation, torqueing, rough shaping, or forcing the movement of the device may damage or deform the distal end and cause potential patient harm. This may also cause the sensing electrodes to become detached and or break off the device.

Care should be taken when handling the distal end of the device near the electrode with surgical instruments – do not squeeze or clamp the electrode. Do not cut or tear silicone.

The coagulation device is only suitable for use with the compatible AtriCure RF generator, cables, and accessories. Use of another manufacturer's accessories may cause damage to the device and/or injury to the patient.

The use and proper placement of an Indifferent Electrode is a key element in the safe and effective use of electrosurgery, particularly in the prevention of patient burns.

Ensure entire area of electrode is reliably attached to the patient's body.

Implantable cardioverter/defibrillators can be adversely affected by RF signals.

### ⚠️ WARNINGS ⚠️

Simultaneous epicardial and endocardial mapping or ablation may result in cardiac injury.

Additional warnings and precautions can be found in the Compatible AtriCure RF Generator Operators Manual (CS-3000 or MAG). Failure to follow the instructions contained in the RF Generator manual may lead to an inability to complete the procedure.

### ⚠️ WARNING ⚠️



This device contains small amounts of Cobalt (CAS# 7440-48-4). Do not use the device if the patient has sensitivity to Cobalt as this may result in an adverse patient reaction.

### ⚠️ CAUTIONS:

- Precautionary measures should be taken prior to considering treatment of patients:
  - Deemed to be high risk and who may not tolerate a potential delayed post-procedure inflammatory pericardial effusion.
  - Who may not be compliant with needed follow-ups to identify potential safety risks.
- To ensure patients undergoing treatment with the EPI-Sense device are well informed, the benefits, potential risks and procedural outcomes associated with the EPI-Sense Hybrid Convergent procedure should be discussed with the patient. Physicians should document accordingly in the medical record.
- Qualified operators are physicians authorized by their institution to perform surgical subxiphoid pericardial access.
- Operators should complete training on the use of EPI-Sense device before performing the procedure.
- Interference produced by the operation of high-frequency surgical equipment may adversely affect the operation of other electronic medical equipment such as monitors and imaging systems. Rearrange monitoring device cables so they do not overlap the Coagulation System cables.
- Coagulation devices have pre-set power and time settings for optimal coagulation. Changing these settings may cause coagulation dimension to vary from the values given in this document.
- Safety and effectiveness of concomitant left atrial appendage closure was not evaluated in the CONVERGE study.

### Potential Complications of the Coagulation Procedure

- Infection
- Cardiac tamponade/perforation
- Pulmonary vein stenosis
- Vessel injury
- Pericardial effusion
- Tissue perforation
- Excessive bleeding
- Phrenic nerve injury
- Left atrial rupture/perforation
- Mediastinitis
- Pulmonary edema
- Vascular access complication
- Stroke/TIA
- Incisional herniation
- Esophageal injury
- Pleural effusion
- Atrio-Esophageal Fistula
- Cardiac arrest/Myocardial infarction
- New arrhythmias
- Thromboembolic complication
- Neurologic complication
- Death
- Complete heart block requiring permanent pacemaker implantation
- Pericarditis
- Serious skin burn
- Transdiaphragmatic herniation
- Damage (e.g., burn, puncture) to other adjacent structures

### Required Equipment/Supplies

- 0.9% Normal Room Temperature Saline Solution (250 mL bag recommended)
- Sterile Perfusion/IV Tubing Set (10 Drops/mL)
- Sterile Vacuum Tubing Set
- Vacuum regulated to -400 mmHg (-533 mbar; -15.75 inHg; -40 cmHg; -7.73 psi; -400 torr; -53 kPa)

### Recommended Optional Equipment/Supplies


- .035"J" Guidewire 100cm
- Endoscope - see Cannula IFU scope recommendations
- 0.9% Normal Saline or Sterile Water
- Temporary external electrogram recording device that meets the following specifications: Complies with IEC 60601-1 and system accepts shielded 2mm pin connectors

### Instructions for Use

#### Device Set Up

1. Place the indifferent, dispersive (return) electrode on patient, per Fig. 3, and connect cable to front of generator (Figure 2.A, #2 and Figure 2.B, #5). Ensure entire area of electrode is reliably attached to the patient's body.


FIG. 3. PLACEMENT OF INDIFFERENT, DISPERSIVE ELECTRODE



2. Place generator footswitch near the surgeon and connect the footswitch cable to front of generator. Refer to 2.A #3 or Figure 9.B #7. Refer to the AtriCure compatible RF Generator Operators Manual for complete generator instructions.
3. Inspect all trays, pouches, cartons, and packaging to ensure there has been no package damage which may result in product contamination. If package damage is discovered, do not use – replace the product.

- Outside the sterile field, remove the device and cable from cartons.
- Inside the sterile field, remove device from the tray and place near patient.
  - Remove the device from the tray by releasing the tabs (Fig. 4, #3).
  - Remove the Touhy Borst fitting from the tray and attach to guide wire exit port on the handle (Fig. 4, #4).

**FIG. 4. COAGULATION DEVICE IN TRAY**



(1) Handle; (2) Stopcock; (3) Tabs; (4) Touhy Borst fitting (5) Distal End

**⚠ WARNING ⚠**

Using excess force to remove the device from the tray may result in damage to the device.


**4. Prepare the Vacuum**

- Attach one end of the sterile vacuum tubing to the graduated fitting where indicated on device handle by the vacuum symbol ('VAC') and the other to the vacuum trap (Fig 5, #6). Use the stopcock to apply and release the vacuum to the distal assembly.
- Ensure the vacuum unit pressure is set to -400 mmHg +/-25 mmHg (-7.7 +/-0.5 psi; -53 +/-3 kPa).

**⚠ WARNING ⚠**

Do not set vacuum to pressures outside of -375 to -425 mmHg (-7.25 to -8.22 psi; -50.0 to -56.7 kPa) - deviating from this pressure range may reduce suction capabilities, reduce tissue contact, or cause tissue damage.

**FIG. 5. COAGULATION DEVICE SETUP**



(1) Perfusion Port; (2) Line to Saline Bag; (3) RF Cable CSK-2000; (4) Guidewire Exit; (5) Stopcock; (6) Stepped Luer to Vacuum tube

**5. Prepare the 0.9% Normal Saline Bag**

- Place unpressurized saline IV bag at patient height or above.

- Connect perfusion tubing to female Luer connection where indicated on device handle by the perfusion "droplet" symbol, Fig. 5, #1. Verify IV line is fully open.
- Insert IV tubing set into 0.9% normal saline bag.
- Turn on vacuum pressure and prime device by engaging the suction with a sterile surface (gloved hand).
- Ensure perfusion flow is functioning by observing drops in IV tubing drip chamber. Make sure the device is primed by observing perfusion at distal end of coagulation device before starting operation of device. Ensure IV line is fully open.

**⚠ WARNINGS ⚠**

Verify that IV line is fully open. Do not pressurize saline bag; that is, do not use an infusion pump for delivery or a pressure bag. Pressurizing saline or partially open perfusion tubing can vary perfusion rate causing loss of suction and the coagulation dimensions to vary from values listed, and cause tissue perforations from excess heating.

Ensure device is primed prior to first RF power delivery to prevent unintended tissue damage.

Ensure perfusion/IV tubing is connected to the handle at the "droplet" symbol – do not connect perfusion tubing to stopcock or "Guide Wire Exit".

Ensure arrows on cable and handle are aligned and cable is completely connected. Device will not register on generator if cable is incorrectly connected.


**⚠ CAUTION:** Use ONLY 0.9% normal saline to prevent unintended tissue damage.

**⚠ CAUTION:** Cables to surgical electrodes should be positioned to prevent contact with patient or other leads

- Connect RF cable CSK-2000 to device handle where indicated by the 'RF' symbol - blue connection to blue connection, Fig. 5, #3 & Fig. 6, #4.


- If using the CSK-2030: Connect the black end of the CSK-2030 Sensing Cable to the generator front panel connector (Fig. 2, & Fig 6, #1).
- Connect the black end of the CSK-2000 RF Cable to the black Bessel receptacle of the CSK-2030 Sensing Cable per the Fig. 6, #3.
- If not using the CSK-2030 Sensing Cable: Connect the black end of the CSK-2000 cable to the coagulation device connection on the generator front panel (Refer to the Operators Manual for complete generator instructions).

**FIG. 6. SENSING SYSTEM CONNECTION USING CSK-2030 NEW STYLE**



Sensing System Connection using 2030 Cable old style





#### EQUIPMENT


- (A) Compatible AtriCure RF Generator;  
(B) CSK-2030 Sensing Cable;  
(C) CSK-2000 RF Cable;  
(D) CDK-1413 Device

#### CONNECTIONS

- (1) CSK-2030 to Compatible AtriCure RF Generator  
(2) CSK-2030 to Sensing Equipment  
(3) CSK-2000 to CSK-2030  
(4) CSK-2000 to CDK-1413

7. When connecting the shrouded pins from Cable CSK-2030 (Fig 6, #2) to the ECG recorder equipment refer to Fig 7 below.
- a) Sensing electrodes provide the option to transmit signal directly from the probe to a commercially available electrogram recording system. This provides the option to sense and record directly from the device to aid in lesion assessment.

**FIG. 7. SENSING ELECTRODE LOCATIONS**




1. Distal #1 Sensing Electrode = CSK-2030 Shrouded Pin #1
2. Distal #2 Sensing Electrode = CSK-2030 Shrouded Pin #2
3. Proximal #3 Sensing Electrode = CSK-2030 Shrouded Pin #3
4. Proximal #4 Sensing Electrode = CSK-2030 Shrouded Pin #4
5. Coagulation Electrode
6. Reference Dots

#### ⚠ WARNING ⚠


Ensure inputs from the ECG recorder are isolated from earth ground, if not, there is an increased possibility of fibrillation.

**FIG. 8. SENSING ELECTRODE SPACING IN MM**




8. Connect power cable to generator back panel connector (Fig. 9.A, #2 or Fig. 9.B #8) then power on the generator via the Power ON/OFF rocker switch (Fig. 9.A, #1 or Fig. 9.B #8). Refer to the Operator Manual for complete generator instructions.

**FIG. 9.A NCONTACT GENERATOR BACK PANEL KEY FEATURES**



**FIG. 9.B MAG GENERATOR BACK PANEL KEY FEATURES**



- (1) - HDMI port; (2) and (3) - PSS pass-through; (4) - USB ports; (5) - Equipotential Connector; (6) - Serial Port; (7) - Footswitch Connector; (8) - Power Switch; (9) - Service Port - AtriCure Only; (10) - Vacuum Port

## OPERATIONAL INSTRUCTIONS

### Manipulation of Guided Coagulation Device Over Accessory Guide Wire

1. Insert the rigid end of the accessory guide wire into the guide tube in the distal end of the guided coagulation device. Ensuring that the floppy end of the guide wire is at the distal end of the coagulation device (Fig. 10).

**FIG. 10. ACCESSORY GUIDE WIRE AND DISTAL END OF COAGULATION DEVICE**




2. Secure the rigid end of the accessory guide wire with a Touhy Borst or stopcock such that the floppy end of the guide wire is in the desired position relative to the distal end of the coagulation device.
3. Advance the guided coagulation device through the Cannula until positioned at desired coagulation location.

## Manipulation of Guided Coagulation Device Over Cannula Guidewire

1. Prepare distal end of device by pre-shaping to give distal tip a slight upward bend as shown in Fig. 11 below.

**FIG. 11. PRE-SHAPED DISTAL END CONFIGURATION**



2. Place Cannula guidewire in desired coagulation location.
3. If attached, remove torquer from end of guidewire.
4. Carefully feed one end of the guidewire into the guide tube in the distal end of guided coagulation device (Fig. 11, #1).
5. Slide coagulation device until guidewire protrudes from handle of coagulation device. If available, attach torquer to the end of guidewire protruding from handle of device.
6. Advance the coagulation device along the guidewire until positioned at desired coagulation location using guidewire to assist in placement.
  - a) Use locator arrows (FIG. 11, #2) to visualize the direction and location of the coagulation electrode during positioning.
  - b) Hold device on desired location until vacuum is engaged.

## Endoscopic Epicardial Access via Subxiphoid Approach

1. Utilizing instructions below, access the epicardial space utilizing a transdiaphragmatic or Subxiphoid approach.

### Subxiphoid Access

1. Standard surgical subxiphoid access of the pericardial space should be performed by a physician authorized by his/her hospital to perform such surgical techniques.
2. Using standard surgical techniques for creating a pericardial window superior to the diaphragm, obtaining access to the posterior surface of the heart.
3. Create an incision immediately inferior to the xiphoid process. Direct visualization of the pericardium superior to the diaphragm can be achieved through the incision. The xiphoid process may be removed, dependent on patient anatomy.
4. A 2 cm incision should be made in the pericardium to allow access for the Cannula. The Cannula provides direct access to the posterior surface of the heart and is sized to create space between the epicardium and the pericardium to visualize cardiac structures and manipulate the coagulation device alongside an endoscope, so all device manipulations are performed under direct visualization.
5. After obtaining subxiphoid access, the EPI-Sense Guided Coagulation Device, Cannula, scopes and surgical instruments are used to create the epicardial lesion pattern.

## Cannula Placement and Manipulation

1. The Cannula should be positioned through the incision and into the pericardial space. As the Cannula is advanced into the pericardial space, it should be directed towards the left of the patient, away from the IVC, as shown in Figure 12.


**FIG. 12. CANNULA PLACEMENT AND MANIPULATION**



## Endoscopic Visualization

1. Use the Cannula to create space so that an endoscope can provide direct visualization of the posterior left atria. When the pericardium is intact and free of adhesions, the Cannula will gently separate the heart from the pericardium and create a cavity into which the device may be advanced under endoscopic visualization.

**FIG. 13. POSTERIOR VIEW OF INFERIOR NEAR LPV**



**FIG. 14. POSTERIOR VIEW OF INFERIOR NEAR RPV**



The Cannula may be manipulated along the posterior heart surface to visualize the left pulmonary veins (LPV) (Figure 13), the right pulmonary veins (RPV) (Figure 14), the inferior vena cava (IVC), the coronary sinus (CS), and the posterior left ventricle (LV). To manipulate the Cannula, use the bevel end to lift the heart. Rotate the Cannula during manipulations to separate the heart from the pericardium and facilitate delineation of anatomic structures. Use the left to visualize tissue structures and assist in creating space. It is best to have the tip of the Cannula against the pericardium as opposed to the heart surface.

## Tissue Coagulation

### ⚠ WARNING ⚠

Esophageal temperature monitoring should be utilized during epicardial and endocardial ablation to prevent damage to the esophagus. If esophageal temperature increases more than 0.5 °C (0.9 °F) during each ablation or above an absolute maximum of 38.0 °C (100.4 °F), RFenergy should be terminated until temperature reduces to baseline or under 37 °C (98.6 °F).

1. Ensure all steps of device set-up are performed.
2. Select the power mode of operation on the generator

### ⚠ WARNING ⚠

Care should be taken to ensure lesions overlap in order to achieve exit block.

3. Place device in desired location by direct visualization. Engage vacuum by turning the stopcock.
4. Ensure contact between the electrode and cardiac tissue by;
  - a) Using locator arrows (Fig 11, #2) to visualize the direction and location of the coagulation electrode
  - b) Reference dots designate the exposed ablative area of the coagulation coil.
  - c) Direct visualization of the device against cardiac tissue after initiation of vacuum;
  - d) Visual observation of saline perfusion from the unpressurized saline bag at a rate of approximately 1 drop per second through the drip chamber while vacuum is initiated.

5. Use the sensing electrodes as a secondary aid to confirm contact with cardiac tissue.
  - a) Pre-Coagulation with the vacuum engaged: check ECG recorder to visualize cardiac tissue waveforms.
6. Fill Cannula with approximately 10 to 20 mL of room temperature saline or sterile water. Saline or sterile water may be administered via the Cannula stopcock or directly through the Cannula. See Cannula IFU for stopcock set-up.
7. Initiate power by pressing and releasing the footswitch or RF ON/OFF button on generator front panel. An audible signal will sound at the beginning of the RF cycle.
8. Coagulate tissue for pre-determined cycle.

Device Code and Size	Power Watts	Time Sec	Average Lesion Dimensions		
			Depth mm	Length mm	Width Mm
CDK-1413, 3cm	30*	90*	7	35	10

\*Automatic cycles have been pre-determined for optimal tissue coagulation.

9. When the generator completes a cycle, RF energy turns off automatically, and an audible completion beep sounds for 1 second.
10. Suction saline or sterile water from pericardial space using Cannula suction to improve visibility. Reference Cannula IFU for suction set-up.

#### ⚠ WARNING ⚠

Ensure that fluid in pericardial space is aspirated during manipulation. Failure to do so may compromise visibility and device placement, leading to patient harm.

11. After the cycle is complete, disengage vacuum from the distal end of the device by turning the stopcock lever.
12. Remove the distal end of coagulation device from tissue and observe completeness of lesion.
13. Place device electrode in next desired location using guidewire if desired.
  - a) After reactivating the vacuum, ensure perfusion flow is functioning by observing drops in IV tubing drip chamber.
14. Check for cardiac signals from the sensing electrodes.
15. **Repeat steps 4-13 from above as needed until desired lesions have been completed.**

#### ⚠ WARNING ⚠

The Epi-Sense Coagulation Device has a limited functional life; if greater than 30 ablation cycles are completed and additional ablations cannot be performed, replace device.

16. At completion of procedure, remove device from tissue, disconnect all cables and tubes and discard device, tubing sets, and CSK-2000 cable following local governing ordinances and recycling plans for disposal or recycling of device components.
  - a) CSK-2030 is a reusable cable; see the cable IFU for instructions on cleaning and reuse.
17. Insert a pericardial drain through the pericardial window and into the pericardial space. Close the incisions leaving the drain to remove fluid from the pericardial space.

⚠ **CAUTION:** Positioning and manipulation of the coagulation device without a guide wire inserted into the guide tube may cause the guide tube to kink. Avoid inserting guidewire into kinked guide tube. Bending device without guidewire in guide tube may kink the guide tube. Avoid inserting guidewire into a kinked guide tube.

#### ⚠ WARNINGS ⚠

Ensure device is disposed of following local governing ordinances and recycling plans to prevent biohazard exposure.

To avoid interruption of vacuum or perfusion flow, do not leave device tubing clamped during coagulation of tissue.

Large blood clots and tissue particles may clog vacuum lumen and impair suction.

To avoid tissue damage: Do not move the device if vacuum is engaged.

Do not torque coagulation device if distal end is curved as damage to device may occur and the electrodes may separate and/or break off from the device.

Visualize the distal end of the device, to ensure it is not pinching/entrapping tissue with other devices, such as the optional Cannula.

Care should be taken when handling the distal end of the device near the electrode with surgical instruments – do not squeeze or clamp the electrode. Do not use tools on the electrode coil, place tools on silicone only as the electrodes may separate and/or break off from the device.

⚠ **CAUTION:** Ensure device is properly connected – switching connections may cause inadequate tissue contact and reduced functionality.

#### ⚠ WARNING ⚠

Temporarily unused active electrodes should be stored in a location isolated from the patient. Failure to do so may lead to patient burns.

#### Epicardial Lesion Creation

1. Prior to creating any lesions, retract the TEE probe (if used) and the NG/OG tube (if used) to the upper third of the esophagus; between 18 – 23 cm (7” to 9”) from the incisors. At a minimum, retract the TEE probe relative to the esophagus, so that the probe is not near the atrium.
2. The upper alarm limit of the temperature probe should be set to 38.0°C (100.4 °F). The preset power and time settings for ablation with the coagulation device are based on extensive testing; changing the settings may cause excessive heating and tissue damage.
3. Prior to ablation, connect a stopcock in-line between the vacuum port and the tapered adaptor to control vacuum through the Cannula.
4. During ablation, room temperature saline should be administered through the Cannula to cool and hydrate the pericardium and underlying anatomy. Before injecting the saline, turn the Cannula vacuum off by closing the in-line stopcock.

#### ⚠ WARNING ⚠

Esophageal temperature monitoring should be utilized during epicardial and endocardial ablation. If esophageal temperature increases more than 0.5 °C (0.9 °F) during each ablation or above an absolute maximum of 38.0 °C (100.4 °F), RF energy should be terminated until temperature reduces to baseline or under 37 °C (98.6°F).

\***Note:** Baseline temperature should be taken prior to any lesion creation.

#### Lesion Location

1. Access the recommended anatomical locations endoscopically and create the epicardial lesions (see clinical study section for lesion map) based on patient anatomy and physician discretion.
  - Left Antral Posterior Pulmonary Vein Orifice Lesion
  - Right Antral Posterior Pulmonary Vein Orifice Lesion
  - Posterior Parallel Vertical Connecting Lesions
  - Left Antral Anterior Pulmonary Vein Orifice Lesion
  - Right Antral Anterior Pulmonary Vein Orifice Lesion




2. Completion of each lesion may require multiple device placements and applications of energy delivery.

### Posterior Left Atrial Lesions

1. To create lesions along the posterior left atrium, medial to the RPVs or the LPVs, position the Cannula under the left atrium. Once in the proper location, use the Cannula to separate the pericardium to create space and allow visualization of the posterior anatomy. This is achieved with the tip of the Cannula facing the pericardium (cleft facing the heart, shown in Figure 15). This maneuver will create a space for the device. Once the Cannula is at the desired location, advance the device such that the ablating coil is in the appropriate location, with coils facing the heart.


**FIG. 15. DEVICE ORIENTATION**



2. Retract the Cannula until the sensing and coagulation electrodes are distal to the Cannula tip and in contact with the left atrium. This will allow the heart to better sit against the device. Always ensure proper orientation of the exposed ablation coil electrode under endoscopic visualization, utilizing the directional arrows and black stripe on back of device to confirm contact with atrial tissue only.
3. Continue to manipulate Cannula and device such that lesions on the posterior LA are adjacent to one another. Repeat lesions until ablation of posterior LA is complete.
4. To avoid deformation of the pericardial reflections or the ablation device and the misdirection of RF energy delivery, do not use excessive force when advancing the device against the reflections. Retract the Cannula until the sensing and coagulation electrodes are distal to the Cannula tip and in contact with the LA. Multiple applications of RF energy may be required to create the desired posterior left atrial lesion, with the 3 cm (1.2") device. Always confirm that the ablation coil arrows are directed toward the heart, away from the pericardium.
5. Epicardial lesions are visible and connection of discrete lesions provides confirmation of lesion continuity. Use the endoscope to facilitate manipulation of the Cannula when confirming that the lesions intersect.

### Left Atrial Lesions


**FIG. 16. LEFT ANTRAL LESIONS**



To position the device along the antral aspect of the left pulmonary vein, (Figure 16), endoscopically identify the LPVs. Once in position, gently rotate the Cannula clockwise to create space between the left atrium and the pericardium with the cleft toward the


PVs and the tip toward the pericardium. When the desired Cannula location is obtained, advance the device such that it passes anterior to the superior LPV and the exposed side of the RF coil (arrows pointing towards the left atrium, Figure 17), faces the left atrium. Remember that in most cases, the superior LPV is anterior to the inferior LPV. Use caution when advancing the device, to not exert excessive force. Engage the vacuum and retract the Cannula until the sensing and coagulation electrodes are distal to the Cannula tip and in contact with the left atrium.

**FIG. 17. DEVICE ORIENTATION TO THE SUPERIOR LPV**



### Right Atrial Lesions


**FIG. 18. RIGHT ANTRAL LESIONS**



The anterior right atrium (Figure 18) can be accessed by rotating the Cannula anterior to the IVC. To position the Cannula anterior to the IVC, endoscopically identify the IVC and position the Cannula adjacent to the IVC from the posterior left atrium. After visual conformation of the IVC, right atrium and pericardium, the Cannula is rotated counterclockwise to position the Cannula between the right atrium and pericardium with the cleft of the Cannula directed toward the IVC and tip of the Cannula toward the pericardium

1. With the Cannula positioned over the IVC, the ablation device may be advanced such that the coagulation electrode is located along the anterior orifice, between the RPV antrum and the right atrium (Figure 19). The Cannula may be used to create space between the pericardium and the atria, allowing the coagulation electrode to seat against tissue. The Cannula also helps separate the pericardium (and phrenic nerve) from the atrium, permitting the ablation device to be positioned along the Waterston's groove region that defines the interatrial junction. A lesion may be created at the left orifice to the RPV antrum.

**FIG. 19. DEVICE LOCATION FOR RIGHT ANTRAL LESIONS**



#### **Transseptal Access and Conventional Endocardial Catheter Ablation – (Refer to Catheter manufacturer's Instructions for Use):**

1. Transseptal access and conventional endocardial catheter ablation should be performed by a physician authorized at his/her hospital to perform such procedures.
2. Obtain venous vascular access using appropriate introducers to insert diagnostic and ablation catheters into the right and left atria.
3. Use appropriate technique to obtain transseptal access to the left atrium after completion of the epicardial lesions. The patient should be heparinized before or after transseptal access is obtained to maintain a target ACT between 300 and 400 seconds to prevent thrombus formation.

**⚠ CAUTION:** Esophageal temperature monitoring should be utilized during endocardial ablation. If esophageal temperature increases more than 0.5 °C (0.9 °F) during each ablation or above an absolute maximum of 38.0 °C (100.4 °F), RF energy should be terminated until temperature reduces to baseline or under 37 °C (98.6 °F). The esophageal temperature probe should be positioned under fluoroscopic guidance directly posterior to the LA at the same level as the tip of the ablation catheter during endocardial ablation.

4. Using standard mapping techniques and diagnostic catheters, the locations of breakthrough between discrete epicardial lesions are detected. The Ablation Catheter is then used to ablate these locations. If additional locations of breakthrough along an epicardial lesion are suspected the endocardial ablation catheter may be used to ensure lesion completeness. Complete the following as indicated by breakthrough locations;
  - Right Superior Pulmonary Vein Lesions
  - Right Inferior Pulmonary Vein Lesions
  - Left Superior Pulmonary Vein Ridge Lesions
  - Cavotricuspid Isthmus (Typical Atrial Flutter) Lesions
5. Once all endocardial lesions are created and confirmation of lesion completeness is achieved, including pulmonary vein isolation and bi-directional block, all catheters and sheaths are removed and vascular access sites closed using standard technique.

## **POST OPERATIVE CARE**

### **Postoperative mitigations for Pericarditis and/or Inflammatory Pericardial Effusions**

1. To mitigate the potential of pericarditis, pericardial effusion or delayed onset cardiac tamponade, the following postoperative care is recommended:
  - Drain management: Leave pericardial drain in the pericardial space (until drainage is less than 50 mL over at least 12 hours is preferable)
  - Prophylactic anti-inflammatory agents (e.g. NSAIDs or Colchicine). A three (3) week duration is recommended.
  - Use of diuretics as needed
  - Echocardiogram should be performed between 1-3 weeks post-procedure and whenever there are suggestive symptoms or signs to screen for late onset pericardial effusion

- Patient education regarding symptoms of pericarditis, pericardial effusion and cardiac tamponade. Patients should be closely monitored for suspected symptoms, which should be further evaluated with appropriate imaging tests.
2. Follow-up should be conducted at approximately 30 days post-procedure to monitor for signs of delayed onset pericarditis or pericardial effusion.

### **Anticoagulation and Anti-arrhythmic therapy management**

1. Anticoagulation management should be followed per the 2017 HRS Expert Consensus on Catheter and Surgical Ablation of Atrial Fibrillation, including:
  - Systemic anticoagulation therapy should be initiated for all patients post procedure through at least two months following the ablation procedure.
  - Decisions regarding the use of systemic anticoagulation more than two months following ablation should be based on the patient's risk factors for stroke and not on the presence or type of AF.
2. Anti-arrhythmic drug management post ablation should be per physician judgment.

## **TRAINING RECOMMENDATIONS**

### **Training plan for new operators**

New operators are defined as de novo operators or those who have completed fewer than 5 cases with the EPI-Sense device. New operators should complete the following training:

1. Participate in a training and education module on the Instructions For Use and best practices with emphasis on the indication and risk mitigation strategies related to pericardial effusion, atrioesophageal fistula (AEF) and stroke.
2. Peer-to-peer education (in-person or online) with focus on the above areas.
3. Pre-lab didactic review covering the salient points from (1) followed by cadaver or comparable simulated models training with the EPI-Sense device.
4. Proctoring by a trained physician and /or a certified AtriCure training specialist for first 5 clinical (human) cases.

### **Training plan for current operators**

1. Current operators will be provided a training and education module on the instruction for use and best practices with emphasis on the indication and risk mitigation strategies related to pericardial effusion, atrioesophageal fistula (AEF) and stroke.
2. Supplemental in-person training course, including case presentation and hands-on training, will also be available for current users.

## MAINTENANCE AND TROUBLESHOOTING

(See Compatible AtriCure RF Generator (CS-3000 or MAG) Operators Manual for additional system maintenance and troubleshooting)

Troubleshooting	
Situation	Action(s)
Device is not receiving perfusion flow	<ul style="list-style-type: none"> <li>• Check perfusion connections on device handle</li> <li>• Check perfusion line connection at IV saline bag</li> <li>• Ensure perfusion line is fully open</li> <li>• Ensure saline bag is not empty</li> <li>• Ensure that device perfusion line/IV tubing are not clamped/obstructed/kinked</li> </ul>
Device is connected but does not register pre-set power and time	<ul style="list-style-type: none"> <li>• Check all connections to the generator and to Cable CSK-2030</li> <li>• Check the connection of the patient return electrode to the patient</li> <li>• Check the cable connection at the handle of the device; the arrows on the cable should be aligned with the arrow on the handle. If both arrows are not aligned, disconnect cable and rotate blue end 180° until aligned then reconnect.</li> </ul>
Device does not engage with tissue	<ul style="list-style-type: none"> <li>• Check vacuum connections on device handle</li> <li>• Ensure stopcock lever is in correct position</li> <li>• Check vacuum line connection at trap and vacuum unit and ensure other lines are not open</li> <li>• Check vacuum pressure – should be approximately -400mmHg (-7.7 psi, -53 kPa)</li> <li>• Ensure that device and vacuum unit lines are not clamped/obstructed/kinked</li> <li>• Check that perfusion set-up is per IFU</li> <li>• Ensure that device distal end is shaped to conform to tissue</li> </ul>
Generator shuts down during cycle due to high impedance (High impedance warning will be indicated on Generator)	<ul style="list-style-type: none"> <li>• Check that device is still engaged with tissue (see above if not)</li> <li>• Check for excessive material on device electrode, remove material as required</li> <li>• Check all cable connections including indifferent electrode connection</li> <li>• Re-start coagulation</li> </ul>
No signals are registering on sensing equipment monitors	<ul style="list-style-type: none"> <li>• Check all cable connections. Ensure the cables and shrouded pins are connected per Figures 6 and 7.</li> <li>• Ensure the shrouded pin numbers match the sensing electrodes on the sensing equipment.</li> </ul>
Unable to remove device from guidewire	<ul style="list-style-type: none"> <li>• Remove torquer from end of guidewire</li> <li>• Flush “Guide Wire Exit” port on the handle with saline</li> </ul>

Troubleshooting	
Situation	Action(s)
Generator does not activate cycle (High impedance warning will be indicated on Generator as “OC” which means Open Circuit)	<ul style="list-style-type: none"> <li>• Ensure generator is plugged in and turned on</li> <li>• Check all cable connections; check indifferent electrode connection for correct position and it is adhered to the patient</li> <li>• Ensure device electrode is in direct contact with desired tissue</li> <li>• Check for material on device electrode, remove material as required</li> <li>• Check footswitch connection</li> <li>• Ensure that generator is in “Power Control Mode”</li> <li>• Ensure that Time is not set to “zero”</li> <li>• Refer to generator Operator Manual</li> </ul>
Guidewire will not insert into device	<ul style="list-style-type: none"> <li>• Ensure guidewire is being inserted into guide tube opening at distal end of device</li> <li>• Ensure recommended guidewire is being used</li> <li>• Ensure guide tube opening is not blocked</li> <li>• Ensure device is not kinked</li> </ul>
Device will not advance along Guidewire or through optional nContact Cannula	<ul style="list-style-type: none"> <li>• Ensure guide tube is not kinked</li> <li>• Flush “Guide Wire Exit” port on the handle with saline</li> <li>• Lubricate lumen of Cannula with sterile saline</li> </ul>

## SUMMARY OF CLINICAL STUDIES CONDUCTED FOR ATRIAL FIBRILLATION TREATMENT INDICATION

The CONVERGE study was a prospective, open-label 2:1 randomized controlled (convergent procedure versus standalone endocardial catheter ablation) multi-center pivotal study to evaluate the safety and effectiveness of the EPI-Sense® Guided Coagulation System for the treatment of symptomatic persistent Atrial Fibrillation (AF) in subjects who are refractory or intolerant to at least one Class I and/or III AAD as compared to a standalone endocardial catheter ablation.

The primary effectiveness endpoint was met for the overall study population. The proportion of subjects who were AF/AT/AFL-free absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months postprocedure followup visit was higher in the EPI-Sense group compared to those in the standalone endocardial catheter ablation group.

The CONVERGE study included patients whose AF was sustained beyond 7 days and imposed no upper limit on duration of continuous AF. In a post hoc analysis assessing the impact of hybrid ablation as AF progresses, patients were sub-classified into persistent (>7 days and ≤12 months of continuous AF) and long-standing persistent AF (> 12 months of continuous AF) sub-groups.

The post hoc analysis based on AF classification (persistent AF or longstanding persistent AF) showed evidence of treatment heterogeneity with a larger treatment effect in the longstanding persistent AF sub-population. The benefit-risk profile of hybrid ablation appeared to be more pronounced in longstanding persistent AF patients given the unmet clinical need in this patient population. For completeness, results are presented for the pre-specified all enrolled and treated subjects (N = 153) and the two sub-groups. Because the results for the persistent AF and longstanding persistent AF sub-populations are post-hoc, they should be interpreted with caution, and the reported confidence intervals are not adjusted for multiplicity.

58% (88/153) of all subjects were classified as having Persistent AF (> 7 days to 12 months): 63% (64/102) in the EPI-Sense group compared to 47% (24/51) in the Catheter Ablation group. 42% (65/153) were classified as longstanding persistent AF (> 12 months): 37% (38/102) in the EPI-Sense group and 53% (27/51) in the Catheter Ablation group.

### CONVERGE Study Design

Patients were treated between 1/8/2014 and 8/21/2018. The database for this report reflected data collected through August 2019 and included one hundred fifty-three (153) subjects treated from twenty-five (25) sites in the US and two (2) sites in the UK.

CONVERGE was a prospective, open-label, 2:1 randomized, controlled, multi-center pivotal clinical study. Subjects were randomized in a 2:1 ratio to treatment with either a convergent procedure utilizing the EPI-Sense Guided Coagulation System or a standalone endocardial catheter ablation procedure.

An independent Data Safety Monitoring Board (DSMB) reviewed all safety data throughout the course of the study. A Clinical Events Committee (CEC) adjudicated all Major Adverse Events (MAEs).

### Inclusion and Exclusion Data

Enrollment in the CONVERGE trial was limited to patients who met the following inclusion criteria:

- Age > 18 years; < 80 years
- Left atrium < 6.0 cm (Trans Thoracic Echo - TTE – parasternal 4 chamber view)
- Refractory or intolerant to one AAD (class I and/or III)
- Documentation of persistent AF
- Provided written informed consent

Patients were not permitted to enroll in the CONVERGE study if they met any of the following exclusion criteria:

- Patients requiring concomitant surgery such as valvular repair or replacement, coronary artery bypass graft (CABG) surgery and atrial septal defect closure.
- Left ventricular ejection fraction < 40%
- Pregnant or planning to become pregnant during study
- Co-morbid medical conditions that limit one-year life expectancy
- Previous cardiac surgery
- History of pericarditis
- Previous cerebrovascular accident (CVA), excluding fully resolved TIA
- Patients who have active infection or sepsis
- Patients with esophageal ulcers strictures and varices
- Patients with renal dysfunction who are not on dialysis (defined as GFR ≤ 40)
- Patients who are contraindicated for anticoagulants such as heparin and coumadin
- Patients who are being treated for ventricular arrhythmias
- Patients who have had a previous left atrial catheter ablation for AF (does not include ablation for AFL or other supraventricular arrhythmias)
- Patients with existing ICDs.
- Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment
- Not competent to legally represent him or herself (e.g., requires a guardian or caretaker as a legal representative).


Prior to initiating the study convergent procedure or the standalone endocardial catheter ablation procedure, subjects were excluded if any of the following intra-operative exclusions were met:

1. Presence of left atrial thrombi per immediate pre-operative transesophageal echocardiograph (TEE) for the convergent procedure, and per TEE or intra-cardiac echo (ICE) for the standalone endocardial catheter ablation procedure.
2. Presence of adhesions that would prevent epicardial access to the pericardial space or the creation of the study recommended complete lesion pattern. (Convergent procedure arm only).

### Convergent Procedure

Patients in the EPI-Sense arm underwent the investigational convergent procedure that included epicardial ablation with the EPI-Sense device followed shortly by an endocardial procedure using a permitted endocardial ablation catheter to complete the lesion set (Figure 1).

FIGURE 1: CONVERGENT EPICARDIAL AND ENDOCARDIAL LESION PATTERN





## Follow-up Schedule

All patients were scheduled for follow-up examinations postoperatively at 7-days, 1-month, 3-, 6-, 12-, 18-months, and long-term phone follow-up at 2-, 3-, 4-, 5-years. Adverse events and complications were recorded at all visits. Table 1 summarizes study follow-up visits and required data collection.

**Table 1: Study Follow Up and Required Data Collection**

	Baseline	Pre-procedure	Procedure	7 Days	1 month	3 months	6 months	12 months
Informed Consent for Study Participation	✓							
Inclusion/Exclusion Criteria	✓	✓	✓					
Medical History	✓							
Spiral CT or MRI	✓						✓	
Procedure			✓					
ECG	✓		✓		✓	✓	✓	✓
ECHO (TTE)	✓			✓			✓	
ECHO (TEE)		✓						
24 hour Holter monitor	✓						✓	✓
Documentation of any AF treatments					✓	✓	✓	✓
Medication status Class I and III AADs, cardiac and Anticoagulants	✓		✓	✓	✓	✓	✓	✓
Evaluation of Adverse Events			✓	✓	✓	✓	✓	✓
Six minute walk test	✓							✓
Quality of Life Assessment (QOL)	✓							✓

## Study Endpoints

### Primary Effectiveness Endpoint

The primary effectiveness endpoint was defined as success or failure to be AF/AT/AFL free absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow-up visit.

Rhythm monitoring following the 3-month blanking period consisted of ECG at 3-, 6-, 12- months visits and 24-hour Holter at 6- and 12- months. These data were evaluated by an independent reviewer.

Subjects were considered primary effectiveness failures if any of the following conditions were observed:

- Any electrocardiographically documented AF/AFL/AT episode of 30 sec duration or longer by Holter, event monitor or rhythm strip; or for the full 10 second recording of a standard 12 lead ECG following the 3-month blanking period through the 12 months post procedure follow-up visit.
- The use of a new or an increase in the dose of a previously failed class I or class III AAD following the 3-month blanking period through the 12 months post procedure follow-up visit.
- DC cardioversion for AF/AFL/AT following the 3-month blanking period through the 12 months post procedure follow-up visit.
- Subsequent left-sided catheter ablation for AF/AFL/AT at any time during the 12 months post procedure follow-up visit.
- Catheter ablation for right-sided typical atrial flutter following the 3-month blanking period through the 12 months post procedure follow-up visit.

The primary effectiveness hypothesis for this study was to demonstrate a superiority success rate of the Epi-Sense group over the Catheter Ablation group. The following primary effectiveness hypothesis was evaluated using a chi-square test at a two-sided significance level of 5% to determine if superiority of the treatment arm was attained:

$$H_0 : P_T = P_C \quad \text{vs} \quad H_a : P_T \neq P_C$$

where P = the true percentage of subjects failing to achieve AF/AFL/AT freedom, PT is the true failure rate for the treatment arm and PC for the control arm.

### Secondary Effectiveness Endpoints

- Success or failure to achieve a 90% reduction from baseline AF burden and off all Class I and III AADs at 12-months post procedure
- Success or failure to achieve a 90% reduction from baseline AF burden regardless of their Class I and III AAD status at 12-months post procedure
- Change in QOL measures at 12-months post procedure from baseline values
- Change in 6-minute walk test score from baseline score
- Success or failure to be AF free and off all Class I and III AADs except a previously failed or intolerant Class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow-up visit
- Success or failure to be AF free regardless of Class I and III AAD status following the 3-month blanking period through the 12-months post procedure follow-up visit.

AF burden percentage was captured directly on the Zio patch report and was based on the total time the subject was in AF over the time the subject wore the Zio patch, after artifact removal. A  $\geq 90\%$  change from baseline is based on comparing the post-procedure AF burden percentage to the baseline AF burden percentage recorded on the Holter Monitor.

### Primary Safety Endpoint

The primary safety endpoint for the study was defined as the incidence of major adverse events (MAEs) occurring within 30-days post-procedure that are listed below, for subjects undergoing the convergent procedure.

All MAEs were adjudicated by the Clinical Events Committee (CEC):

- Cardiac tamponade: significant pericardial effusion resulting in hemodynamic compromise, requires elective or urgent pericardiocentesis, and results in a 1 cm or more pericardial effusion as documented by echocardiography.
- Severe Pulmonary Vein Stenosis ( $\geq 70\%$  occlusion)
- Excessive bleeding requiring transfusion or  $> 20\%$  drop in HCT.
- Myocardial infarction
- Stroke
- Transient Ischemic Attacks (TIA)
- Atrioesophageal fistula
- Phrenic nerve injury
- Death

No formal hypothesis testing was pre-specified in the study protocol. Instead, the protocol pre-specified an acceptable MAE rate of 12%. The primary safety endpoint would be considered met if the true incidence rate for MAEs in this study population was no more than 12% with a 95% one-sided upper bound of MAEs being less than 20%.

### Secondary Safety Endpoint

The secondary safety endpoint for the study was the incidence of serious adverse events (SAEs) in the study through the 12-months post procedure visit, in each arm of the study.


### Exploratory Endpoints

- Success or failure to achieve a 90% reduction from baseline AF burden with and without Class I and III AADs at 18 months post procedure
- Change in left ventricular ejection fraction
- Atrial remodeling assessed by a decrease in left atrial size
- Health Economics Data

### Subject Accountability

At the time of the database lock (November 6, 2019), of 153 patients enrolled in the CONVERGE PMA study 96.7% (148/153) patients are available for analysis at the 12-months post-operative visit. Study exit reasons for randomized Epi-Sense subjects included enrollment closure, no insurance coverage, patient withdrew consent, pericardial adhesion, severe liver disease, lung cancer, severe tricuspid regurgitation, severe mitral regurgitation. Figure 2 presents the patient accountability.

FIGURE 2: SUBJECT ACCOUNTABILITY



### Subject Demographics and Baseline Characteristics

A summary of the demographic and baseline characteristics is presented in Table 2 for the all treated population (persistent and longstanding persistent AF subjects) and the longstanding persistent AF sub-population. Baseline cardiovascular comorbidities are summarized in Table 3. Additional baseline and ablation procedure data are summarized in Table 4.

The demographics of the study population are typical for an atrial fibrillation ablation study performed in the US and the UK. As detailed below, except for gender, the treatment groups were comparable with respect to demographic and baseline characteristics.

As detailed below, the major comorbidities were comparable between the Epi-Sense and Catheter Ablation groups. Most subjects 75.2% (115/153) had hypertension: 75.5% (77/102) in the Epi-Sense group and 74.5% (38/51) in the Catheter Ablation group. Most subjects had some type of valvular heart disease: 57.5% (88/153) with mitral valve regurgitation and 56.2% (86/153) with tricuspid valve regurgitation.

**Table 2: Demographics and Baseline Characteristics**

	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
Parameter	Epi-Sense (N = 102)	Catheter Ablation (N = 51)	Epi-Sense (N = 38)	Catheter Ablation (N = 27)
Age (years), Mean ± SD	63.7 ± 9.64	65.1 ± 6.66	61.5 ± 10.27	65.2 ± 7.26
Male	78% (80/102)	53% (27/51)	82% (31/38)	56% (15/27)
Caucasian	94% (96/102)	98% (50/51)	95% (36/38)	96% (26/27)
Height (cm), Mean ± SD	177.7 ± 8.43	173.9 ± 11.64	178.5 ± 9.05	172.7 ± 8.95
Weight (kg), Mean ± SD	104.3 ± 19.98	106.3 ± 23.90	104.3 ± 20.56	105.3 ± 23.10
Body mass index (kg/m²), Mean ± SD	33.0 ± 5.86	35.1 ± 7.13	32.7 ± 5.97	35.4 ± 7.88
Number of years in atrial fibrillation [a]	4.4 ± 4.8	4.5 ± 4.7	6.0 ± 6.4	5.8 ± 5.5
Type of atrial fibrillation				
Persistent	63% (64/102)	47% (24/51)	0% (0/35)	0% (0/27)
Longstanding Persistent	37% (38/102)	53% (27/51)	100% (35/35)	100% (27/27)

[a] The number of years since persistent AF diagnosis.

**Table 3: Baseline Cardiovascular Comorbidities**

	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
Parameter	Epi-Sense (N = 102)	Catheter Ablation (N = 51)	Epi-Sense (N = 38)	Catheter Ablation (N = 27)
1st Degree AV Block	5.9% (6/102)	3.9% (2/51)	2.6% (1/38)	3.7% (1/27)
Acute MI	4.9% (5/102)	2.0% (1/51)	5.3% (2/38)	0.0% (0/27)
Aortic Atherosclerosis	4.9% (5/102)	2.0% (1/51)	5.3% (2/38)	0.0% (0/27)
Aortic Valve Regurgitation	18.6% (19/102)	13.7% (7/51)	10.5% (4/38)	11.1% (3/27)
Atrial Flutter	9.8% (10/102)	15.7% (8/51)	13.2% (5/38)	14.8% (4/27)
Bradycardia	8.8% (9/102)	11.8% (6/51)	5.3% (2/38)	11.1% (3/27)
Cardiomyopathy	14.7% (15/102)	7.8% (4/51)	26.3% (10/38)	11.1% (3/27)
Congestive Heart Failure (CHF)	17.6% (18/102)	27.5% (14/51)	2.6% (1/38)	25.9% (7/27)
Coronary Artery Disease (CAD)	19.6% (20/102)	19.6% (10/51)	26.3% (10/38)	18.5% (5/27)
Hypertension	75.5% (77/102)	74.5% (38/51)	73.7% (28/38)	77.8% (21/27)
Left Ventricular Dysfunction	3.9% (4/102)	2.0% (1/51)	0% (0/38)	3.7% (1/27)
Mitral Valve Prolapse	2.0% (2/102)	5.9% (3/51)	0% (0/38)	3.7% (1/27)
Mitral Valve Regurgitation	53.9% (55/102)	64.7% (33/51)	50.0% (19/38)	55.6% (15/27)
Peripheral Vascular Disease	2.0% (2/102)	7.8% (4/51)	2.6% (1/38)	7.4% (2/27)
Pulmonary Valve Incompetence	2.9% (3/102)	3.9% (2/51)	2.6% (1/38)	0.0% (0/27)
Sick Sinus Syndrome	4.9% (5/102)	2.0% (1/51)	2.6% (1/38)	0.0% (0/27)
Tachycardia	2.9% (3/102)	3.9% (2/51)	7.9% (3/38)	3.7% (1/27)
Tricuspid Valve Regurgitation	52.9% (54/102)	62.7% (32/51)	50.0% (19/38)	51.9% (14/27)

**Table 4: Additional Baseline and Ablation Procedure Data**

	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
Parameter	EPI-Sense (N = 102)	Catheter Ablation (N = 51)	EPI-Sense (N = 38)	Catheter Ablation (N = 27)
Ablation Procedure Time (Minutes)				
Total Convergent Procedure Time [a]	293.9 ± 80.4	Not Applicable	301.9 ± 60.4	Not Applicable
Total Epicardial Procedure Time [b]	115.8 ± 35.5	Not Applicable	116.1 ± 27.7	Not Applicable
Total Epicardial Ablation Procedure Time [c]	69.5 ± 21.2	Not Applicable	77.3 ± 19.9	Not Applicable
Total Epicardial RF Time [d]	42.9 ± 13.7	Not Applicable	45.0 ± 13.3	Not Applicable
Total Endocardial Ablation Procedure Time [e]	135.8 ± 49.9	171.4 ± 59.7	139.6 ± 44.1	180.7 ± 64.1
Total Time to Create Endocardial Lesion [c]	82.6 ± 42.6	113.3 ± 48.5	83.6 ± 35.5	110.9 ± 54.6
Total Endocardial RF Time [d]	40.0 ± 22.1	61.3 ± 25.7	43.0 ± 18.1	65.0 ± 26.6
Left Atrial Diameter (cm)	4.4 ± 0.62	4.3 ± 0.56	4.5 ± 0.68	4.3 ± 0.56
Left ventricular ejection fraction (%)	55.3 ± 7.79	55.7 ± 6.13	54.4 ± 7.50	54.7 ± 6.22

Note: Data are presented as Mean ± SD.

[a] Abdominal incision to removal of catheters-not sheath pull.

[b] Abdominal incision to abdominal access site closure.

[c] Time from first lesion to last lesion.

[d] Cumulative time of RF energy delivery.

[e] Groin access to removal of catheters.

## Primary Safety Results

The primary safety endpoint was defined as the incidence of MAEs for subjects undergoing the convergent procedure for the procedural to 30-day post-procedure time period. A summary of MAEs during is provided in Table 5 below.

In comparison to the EPI-Sense group, no MAEs occurred in the 51 Catheter Ablation subjects. Eight subjects (7.8% (8/102) [95% UCL: 13.7%]) in the EPI-Sense group experienced nine MAEs. One subject experienced a tamponade and an excessive bleeding event. The most commonly reported MAE was a delayed pericardial effusion, occurring in 3.9% (4/102) of subjects. Per the protocol, the observed MAE rate of 7.8% (95% UCL: 13.7%) in this study population was no more than 12% with a 95% one-sided upper bound of MAEs being less than 20%. A total of 3 of 8 MAEs occurred within 7 days post-procedure: excessive bleeding, cardiac tamponade, and stroke.

As per the protocol definition, only those pericardial effusions that had tamponade physiology on echocardiogram and resulted in an intervention for pericardial fluid drainage counted towards the primary safety endpoint. Other than the 4 primary safety endpoint events of tamponade, two additional EPI-Sense subjects experienced pericardial effusion of greater than 1 cm but without tamponade physiology on echocardiogram within 30 days of the procedure. Both subjects were treated with invasive procedure for pericardial drainage. Overall, 6 subjects had pericardial effusion that were drained within 30 days of the procedure. These pericardial effusion events were delayed and likely due to inflammatory response to pericardiotomy and extensive epicardial ablation. In one subject, delayed recognition of symptomatic pericardial effusion/tamponade despite repeated clinical encounters led to cardiac arrest. Subsequently the patient had acute multi-organ dysfunction syndrome and anoxic brain injury.

The results for the persistent AF and longstanding persistent AF sub-populations are considered post-hoc and should be interpreted with caution since the confidence intervals are presented without adjustment for multiplicity.



**Table 5: Primary Safety Endpoint**

Major Adverse Event (MAE)	Protocol Definition	
	All Treated (N = 102)	Longstanding Persistent (N = 38)
Death	0% (0/102)	0% (0/38)
Atrioesophageal Fistula	0% (0/102)	0% (0/38)
Cardiac Tamponade	3.9% (4/102)	2.6% (1/38)
Excessive Bleeding (requiring transfusion)	1% (1/102)	0% (0/38)
Transient Ischemic Attack	1% (1/102)	0% (0/38)
Stroke	1% (1/102)	2.6% (1/38)
Phrenic Nerve Injury	1% (1/102)	2.6% (1/38)
Safety Event (MAE) Rate	7.8% (8/102) <sup>†</sup> [13.7% UCL]	7.9% (3/38) [19.2% UCL] [a]

[a]: Confidence intervals are not adjusted for multiplicity.

†One experienced a tamponade and an excessive bleeding event. The subject is included once in the tamponade event.

Note: No Severe Pulmonary Vein Stenosis; Myocardial Infarction were reported in the trial.

No protocol pre-specified MAEs were observed in the Catheter Ablation arm.

All events resolved without sequelae, except for one patient with the strokes who continues with slightly slower left facial movement and one with unknown recovery due to subject withdrawal.

### Primary Effectiveness Results

The primary effectiveness endpoint was defined as the proportion of subjects who were AF/AT/AFL-free (that is, no episodes > 30 seconds by Holter; or for full 10 second recording on standard 12 lead ECG) absent Class I and III AADs except for a previously failed or intolerant Class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow up visit. The primary effectiveness endpoint analysis is presented for the ITT (with imputation), ITT (without imputation), mITT and Per-Protocol populations in Table 6.1 below.

In the full all treated patient population, the primary effectiveness endpoint of superiority of the Epi-Sense compared to Catheter Ablation was met. Freedom from AF/AFL/AT was achieved in 65.7% (67/102) [95% CI: 56.5%, 74.9%] subjects in the Epi-Sense treatment group compared to 49.0% (25/51) [95% CI: 35.3%, 62.7%] subjects in the Catheter Ablation group. The observed success rate difference of 16.7% [95% CI: 0.1%, 33.2%] is statistically significant (Chi-Squared p-value = 0.0472) in favor of the Epi-Sense treatment group. The success rate difference for the ITT population, without imputation for missing data was 17.7% [95% CI: 1.0%, 34.3%] which is statistically significant (Chi-Squared p-value = 0.0360) in favor of the Epi-Sense treatment group. The result was sustained across the mITT and Per-Protocol populations.

**Table 6.1: Primary Effectiveness Endpoint (All Treated Subjects)**

Primary Effectiveness	All Treated Subjects (N = 153)		
	Epi-Sense (N = 102)	Catheter Ablation (N = 51)	Treatment Difference [c][d]
ITT Population [a]	65.7% (67/102)	49.0% (25/51)	16.7% ( <b>p=0.0472</b> )
95% Confidence Interval	56.5 - 74.9%	35.3 - 62.7%	0.1 - 33.2%
ITT Population [b]	67.7% (67/99)	50.0% (25/50)	17.7% ( <b>p=0.0360</b> )
95% Confidence Interval	58.5 - 76.9%	36.1 - 63.9%	1.0 - 34.3%
mITT Population [a]	67.0% (67/100)	49.0% (25/51)	18.0% ( <b>p=0.0322</b> )
95% Confidence Interval	57.8 - 76.2%	35.3 - 62.7%	1.5 - 34.5%
PP Population [b]	68.0% (66/97)	51.0% (25/49)	17.0% ( <b>p=0.0450</b> )
95% Confidence Interval	58.8 - 77.3%	37.0 - 65.0%	0.2 - 33.8%

Note: The ITT population consists of all subjects who received a randomized study procedure.

The mITT population consists of all subjects who received a randomized study procedure and have at least one post-treatment follow-up visit after the 3-month blanking period with non-missing efficacy results.

The PP population consists of all subjects who received a randomized study procedure, have non-missing efficacy results at the 6-month visit, and have at least four of the five first year visits (e.g., at least 4 of the 7 day, 1 month, 3 month 6 month and 12 month visits are completed) and who have no major protocol violations or deviations.

[a] Subjects with indeterminate results are classified as failures.

[b] Indeterminate (missing) data are not imputed.

[c] Confidence intervals calculated using the Wald asymptotic method.

[d] Difference between treatment arms evaluated using Chi-Squared test.

The results for the longstanding persistent AF sub-population are considered post-hoc and should be interpreted with caution since the confidence intervals are presented without adjustment for multiplicity.

Further analysis revealed evidence of heterogeneity of the treatment effect based on AF class (interaction p-value = 0.1469), primary effectiveness success driven by the longstanding persistent AF sub-population.

### Persistent AF Subjects

Freedom from AF/AFL/AT was achieved in 65.6% (42/64) [95% CI: 54.0%, 77.3%] subjects in the Epi-Sense treatment group compared to 62.5% (15/24) [95% CI: 43.1%, 81.9%] subjects in the Catheter Ablation group. The observed success rate difference was 3.1% [95% CI: -19.5%, 25.7%].

### Longstanding Persistent AF Subjects

Freedom from AF/AFL/AT was achieved in 65.8% (25/38) [95% CI: 50.7%, 80.9%] subjects in the Epi-Sense treatment group compared to 37.0% (10/27) [95% CI: 18.8%, 55.3%] subjects in the Catheter Ablation group. The observed success rate difference was 28.8% [95% CI: 5.1%,

52.4%]. The success rate difference for the Per-Protocol population was 27.3% [95% CI: 3.3%, 51.4%].

**Table 6.2: Post-Hoc Primary Effectiveness Endpoint (Persistent and Longstanding Persistent AF Sub-Populations)**

Primary Effectiveness	Persistent AF Subjects (N = 88)			Longstanding Persistent AF Subjects (N = 65)		
	Epi-Sense (N = 64)	Catheter Ablation (N = 24)	Treatment Difference [c]	Epi-Sense (N = 38)	Catheter Ablation (N = 27)	Treatment Difference [c]
ITT Population [a]	65.6% (42/64)	62.5% (15/24)	3.1%	65.8% (25/38)	37.0% (10/27)	28.8%
95% Confidence Interval	54.0 - 77.3%	43.1 - 81.9%	-19.5 - 25.7%	50.7 - 80.9%	18.8 - 55.3%	5.1 - 52.4%
ITT Population [b]	68.8% (42/61)	65.2% (15/23)	3.6%	65.8% (25/38)	37.0% (10/27)	28.8%
95% Confidence Interval	57.2 - 80.5%	45.8 - 84.7%	-19.0 - 26.3%	50.7 - 80.9%	18.8 - 55.3%	5.1 - 52.4%
mITT Population [a]	67.7% (42/62)	62.5% (15/24)	5.2%	65.8% (25/38)	37.0% (10/27)	28.8%
95% Confidence Interval	56.1 - 79.4%	43.1 - 81.9%	-17.4 - 27.8%	50.7 - 80.9%	18.8 - 55.3%	5.1 - 52.4%
PP Population [b]	69.5% (41/59)	65.2% (15/23)	4.3%	65.8% (25/38)	38.5% (10/26)	27.3%
95% Confidence Interval	57.7 - 81.2%	45.8 - 84.7%	-18.5 - 27.0%	50.7 - 80.9%	19.8 - 57.2%	3.3 - 51.4%

Note: Refer to footnotes on Table 6.1. Confidence intervals are not adjusted for multiplicity.

## Secondary Safety and Effectiveness Results

### Secondary Safety (Serious Adverse Events within 12 months)

The secondary safety endpoint for the study was the incidence of serious adverse events (SAEs) in the study through the 12-months post-procedure, in each treatment arm of the study. A summary of SAEs that occurred through the 12-months post-procedure is provided in the tables below.

SAEs occurring within the 12-months post-procedure period were reported in 32.4% (33/102) subjects in the Epi-Sense group compared to 35.3% (18/51) subjects in the Catheter Ablation group. The most commonly reported SAEs through the 12-months post-procedure period included: cardiac failure congestive (4.9% and 2% of subjects in the Epi-Sense-AF and Catheter Ablation groups, respectively); cardiac tamponade (3.9% of subjects in Epi-Sense-AF group); pericardial effusion (3.9% of subjects in Epi-Sense-AF group); pericarditis (2.9% of subjects in Epi-Sense group); and pneumonia (2.9% and 7.8% of subjects in Epi-Sense and Catheter Ablation groups, respectively). Sinus node dysfunction was reported in 3.9% (2/51) subjects in the Catheter Ablation group.

**Table 7.1: Summary of Serious Adverse Events within 12 months (All Treated Subjects)**

All Treated Subjects (N = 153)				
	EPi-Sense (N = 102)		Catheter Ablation (N = 51)	
System Organ Class MedDRA Preferred Term	Subjects n (%)	Events n	Subjects n (%)	Events n
ANY SERIOUS ADVERSE EVENT	33 (32.4%)	58	18 (35.3%)	22
<b>CARDIAC DISORDERS</b>				
ATRIOVENTRICULAR BLOCK COMPLETE	1 (1.0%)	1	0 (0%)	0
CARDIAC FAILURE CONGESTIVE	5 (4.9%)	5	1 (2.0%)	1
CARDIAC TAMPONADE	4 (3.9%)	4	0 (0%)	0
PERICARDIAL EFFUSION	4 (3.9%)	4	0 (0%)	0
PERICARDITIS	3 (2.9%)	3	0 (0%)	0
SINUS NODE DYSFUNCTION	0 (0%)	0	2 (3.9%)	2
OVERALL INCIDENCE	15 (14.7%)	17	3 (5.9%)	3
<b>ENDOCRINE DISORDERS</b>				
HYPERTHYROIDISM	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	1 (1.0%)	1	0 (0%)	0
<b>GASTROINTESTINAL DISORDERS</b>				
DIVERTICULAR PERFORATION	1 (1.0%)	1	0 (0%)	0
GASTROINTESTINAL HAEMORRHAGE	1 (1.0%)	1	1 (2.0%)	1
GASTROINTESTINAL ULCER HAEMORRHAGE	1 (1.0%)	1	0 (0%)	0
HAEMORRHOIDAL HAEMORRHAGE	0 (0%)	0	1 (2.0%)	1
INTESTINAL OBSTRUCTION	1 (1.0%)	1	0 (0%)	0
NAUSEA	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	5 (4.9%)	5	2 (3.9%)	2
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>				
CHEST PAIN	3 (2.9%)	3	0 (0%)	0
MULTI-ORGAN DISORDER	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	4 (3.9%)	4	0 (0%)	0
<b>INFECTIONS AND INFESTATIONS</b>				
CELLULITIS	0 (0%)	0	1 (2.0%)	1
CHOLECYSTITIS INFECTIVE	1 (1.0%)	1	0 (0%)	0
DIVERTICULITIS	0 (0%)	0	1 (2.0%)	1
ERYSIPELAS	1 (1.0%)	1	0 (0%)	0
INFECTION	0 (0%)	0	1 (2.0%)	1
LOWER RESPIRATORY TRACT INFECTION	1 (1.0%)	1	0 (0%)	0
PNEUMONIA	3 (2.9%)	3	4 (7.8%)	4
UPPER RESPIRATORY TRACT INFECTION	0 (0%)	0	1 (2.0%)	1
URINARY TRACT INFECTION	0 (0%)	0	1 (2.0%)	1
OVERALL INCIDENCE	6 (5.9%)	6	9 (17.6%)	9
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>				
INCISIONAL HERNIA	1 (1.0%)	1	0 (0%)	0
LOWER LIMB FRACTURE	0 (0%)	0	1 (2.0%)	1
NERVE INJURY	1 (1.0%)	1	0 (0%)	0
POST PROCEDURAL HAEMORRHAGE	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	3 (2.9%)	3	1 (2.0%)	1
<b>METABOLISM AND NUTRITION DISORDERS</b>				

FLUID OVERLOAD	2 (2.0%)	2	0 (0%)	0
HYPONATRAEMIA	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	3 (2.9%)	3	0 (0%)	0
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>				
CERVICAL SPINAL STENOSIS	1 (1.0%)	1	0 (0%)	0
MUSCULAR WEAKNESS	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	2 (2.0%)	2	0 (0%)	0
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>				
BREAST CANCER RECURRENT	0 (0%)	0	1 (2.0%)	1
GLIOBLASTOMA	1 (1.0%)	1	0 (0%)	0
INVASIVE DUCTAL BREAST CARCINOMA	1 (1.0%)	1	0 (0%)	0
KAPOSI'S SARCOMA	0 (0%)	0	1 (2.0%)	1
OVERALL INCIDENCE	2 (2.0%)	2	2 (3.9%)	2
<b>NERVOUS SYSTEM DISORDERS</b>				
CEREBROVASCULAR ACCIDENT	1 (1.0%)	1	0 (0%)	0
TRANSIENT ISCHAEMIC ATTACK	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	2 (2.0%)	2	0 (0%)	0
<b>RENAL AND URINARY DISORDERS</b>				
ACUTE KIDNEY INJURY	1 (1.0%)	1	0 (0%)	0
CHRONIC KIDNEY DISEASE	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	2 (2.0%)	2	0 (0%)	0
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>				
ACUTE RESPIRATORY FAILURE	1 (1.0%)	1	0 (0%)	0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	1 (1.0%)	1	0 (0%)	0
CHRONIC RESPIRATORY FAILURE	1 (1.0%)	1	0 (0%)	0
HAEMOPTYSIS	0 (0%)	0	1 (2.0%)	1
ORGANISING PNEUMONIA	0 (0%)	0	1 (2.0%)	1
PLEURAL EFFUSION	2 (2.0%)	2	1 (2.0%)	1
PLEURITIC PAIN	1 (1.0%)	1	0 (0%)	0
PULMONARY OEDEMA	3 (2.9%)	3	0 (0%)	0
OVERALL INCIDENCE	8 (7.8%)	9	3 (5.9%)	3
<b>SURGICAL AND MEDICAL PROCEDURES</b>				
COLOSTOMY CLOSURE	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	1 (1.0%)	1	0 (0%)	0
<b>VASCULAR DISORDERS</b>				
HAEMATOMA	0 (0%)	0	1 (2.0%)	1
HYPERTENSIVE EMERGENCY	0 (0%)	0	1 (2.0%)	1
JUGULAR VEIN THROMBOSIS	1 (1.0%)	1	0 (0%)	0
OVERALL INCIDENCE	1 (1.0%)	1	2 (3.9%)	2

**Table 7.2: Summary of Serious Adverse Events within 12 months**

(Persistent and Longstanding Persistent AF Sub-Populations)

System Organ Class MedDRA Preferred Term	Persistent AF Subjects (N = 88)				Longstanding Persistent AF Subjects (N = 65)			
	EPi-Sense (N = 64)		Catheter Ablation (N = 24)		EPi-Sense (N = 38)		Catheter Ablation (N = 27)	
	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n	Subjects n (%)	Events n
ANY SERIOUS ADVERSE EVENT	23 (35.9%)	37	9 (37.5%)	12	10 (26.3%)	21	9 (33.3%)	10



<b>CARDIAC DISORDERS</b>								
ATRIOVENTRICULAR BLOCK COMPLETE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
CARDIAC FAILURE CONGESTIVE	3 (4.7%)	3	1 (4.2%)	1	2 (5.3%)	2	0 (0%)	0
CARDIAC TAMPONADE	3 (4.7%)	3	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
PERICARDIAL EFFUSION	3 (4.7%)	3	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
PERICARDITIS	1 (1.6%)	1	0 (0%)	0	2 (5.3%)	2	0 (0%)	0
SINUS NODE DYSFUNCTION	0 (0%)	0	0 (0%)	0	0 (0%)	0	2 (7.4%)	2
OVERALL INCIDENCE	11 (17.2%)	11	1 (4.2%)	1	4 (10.5%)	6	2 (7.4%)	2
<b>ENDOCRINE DISORDERS</b>								
HYPERTHYROIDISM	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
<b>GASTROINTESTINAL DISORDERS</b>								
DIVERTICULAR PERFORATION	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
GASTROINTESTINAL HAEMORRHAGE	1 (1.6%)	1	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
GASTROINTESTINAL ULCER HAEMORRHAGE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
HAEMORRHOIDAL HAEMORRHAGE	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
INTESTINAL OBSTRUCTION	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
NAUSEA	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
OVERALL INCIDENCE	4 (6.3%)	4	1 (4.2%)	1	1 (2.6%)	1	1 (3.7%)	1
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>								
CHEST PAIN	1 (1.6%)	1	0 (0%)	0	2 (5.3%)	2	0 (0%)	0
MULTI-ORGAN DISORDER	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	2 (3.1%)	2	0 (0%)	0	2 (5.3%)	2	0 (0%)	0
<b>INFECTIONS AND INFESTATIONS</b>								
CELLULITIS	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
CHOLECYSTITIS INFECTIVE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
DIVERTICULITIS	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
ERYSIPELAS	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
INFECTION	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
LOWER RESPIRATORY TRACT INFECTION	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
PNEUMONIA	3 (4.7%)	3	3 (12.5%)	3	0 (0%)	0	1 (3.7%)	1
UPPER RESPIRATORY TRACT INFECTION	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
URINARY TRACT INFECTION	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
OVERALL INCIDENCE	4 (6.3%)	4	4 (16.7%)	4	2 (5.3%)	2	5 (18.5%)	5
<b>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</b>								
INCISIONAL HERNIA	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
LOWER LIMB FRACTURE	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
NERVE INJURY	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
POST PROCEDURAL HAEMORRHAGE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	1 (4.2%)	1	2 (5.3%)	2	0 (0%)	0
<b>METABOLISM AND NUTRITION DISORDERS</b>								
FLUID OVERLOAD	0 (0%)	0	0 (0%)	0	2 (5.3%)	2	0 (0%)	0
HYPONATRAEMIA	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	0 (0%)	0	2 (5.3%)	2	0 (0%)	0

**Table 7.2: Summary of Serious Adverse Events within 12 months**

(Persistent and Longstanding Persistent AF Sub-Populations)

	Persistent AF Subjects (N = 88)				Longstanding Persistent AF Subjects (N = 65)			
	Epi-Sense (N = 64)		Catheter Ablation (N = 24)		Epi-Sense (N = 38)		Catheter Ablation (N = 27)	
<b>System Organ Class MedDRA Preferred Term</b>	<b>Subjects n (%)</b>	<b>Events n</b>	<b>Subjects n (%)</b>	<b>Events n</b>	<b>Subjects n (%)</b>	<b>Events n</b>	<b>Subjects n (%)</b>	<b>Events n</b>
<b>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</b>								
CERVICAL SPINAL STENOSIS	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
MUSCULAR WEAKNESS	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	2 (3.1%)	2	0 (0%)	0	0 (0%)	0	0 (0%)	0
<b>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)</b>								
BREAST CANCER RECURRENT	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
GLIOBLASTOMA	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
INVASIVE DUCTAL BREAST CARCINOMA	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
KAPOSI'S SARCOMA	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	2 (8.3%)	2	1 (2.6%)	1	0 (0%)	0
<b>NERVOUS SYSTEM DISORDERS</b>	0 (0%)	0	0 (0%)	0	0 (0%)	0	0 (0%)	0
CEREBROVASCULAR ACCIDENT	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
TRANSIENT ISCHAEMIC ATTACK	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
<b>RENAL AND URINARY DISORDERS</b>								
ACUTE KIDNEY INJURY	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
CHRONIC KIDNEY DISEASE	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>								
ACUTE RESPIRATORY FAILURE	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
CHRONIC RESPIRATORY FAILURE	0 (0%)	0	0 (0%)	0	1 (2.6%)	1	0 (0%)	0
HAEMOPTYSIS	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
ORGANISING PNEUMONIA	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
PLEURAL EFFUSION	1 (1.6%)	1	0 (0%)	0	1 (2.6%)	1	1 (3.7%)	1
PLEURITIC PAIN	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
PULMONARY OEDEMA	3 (4.7%)	3	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	5 (7.8%)	6	2 (8.3%)	2	3 (7.9%)	3	1 (3.7%)	1
<b>SURGICAL AND MEDICAL PROCEDURES</b>								
COLOSTOMY CLOSURE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
<b>VASCULAR DISORDERS</b>								
HAEMATOMA	0 (0%)	0	0 (0%)	0	0 (0%)	0	1 (3.7%)	1
HYPERTENSIVE EMERGENCY	0 (0%)	0	1 (4.2%)	1	0 (0%)	0	0 (0%)	0
JUGULAR VEIN THROMBOSIS	1 (1.6%)	1	0 (0%)	0	0 (0%)	0	0 (0%)	0
OVERALL INCIDENCE	1 (1.6%)	1	1 (4.2%)	1	0 (0%)	0	1 (3.7%)	1

Secondary Safety (Serious Adverse Events Related to Device and/or Procedure within 12 months)

Table 8 presents device or procedure related SAEs through 12 months by treatment group and AF type. Device/Procedure-related SAE rate is 19.6% (20/102) in the Epi-Sense arm, and 9.8% (5/51) in the catheter ablation arm.

**Table 8: SAEs Related to device and/or procedure through 12 months post-procedure**

Parameter	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
	EPI-Sense (N = 102)	Catheter Ablation (N = 51)	EPI-Sense (N = 38)	Catheter Ablation (N = 27)
<b>Number of subjects with events</b>	19.6% (20/102)	9.8% (5/51)	18.4% (7/38)	7.4% (2/27)
<b>Cardiac Events</b>	13.7% (14/102)	2.0% (1/51)	15.7% (6/38)	0.0% (0/27)
Cardiac Tamponade* [a]	3.9% (4/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Chest pain	1.0% (1/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Congestive Heart Failure	2.0% (2/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Hypertensive Emergency	0.0% (0/102)	2.0% (1/51)	0.0% (0/38)	0.0% (0/27)
Pericardial Effusion [b]	3.9% (4/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Pericarditis	2.9% (3/102)	0.0% (0/51)	5.3% (2/38)	0.0% (0/27)
<b>Respiratory Events</b>	4.9% (5/102)	3.9% (2/51)	5.3% (2/38)	3.7% (1/27)
Acute Respiratory Failure	1.0% (1/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Pneumonia	1.0% (1/102)	2.0% (1/51)	0.0% (0/38)	0.0% (0/27)
Pleural Effusion	2.0% (2/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Upper Respiratory Infection	0.0% (0/102)	2.0% (1/51)	0.0% (0/38)	3.7% (1/27)
Pulmonary Edema	1.0% (1/102)	0.0% (0/51)	0.0% (0/38)	0.0% (0/27)
Excessive Bleeding*	2.0% (2/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Phrenic Nerve Injury*	1.0% (1/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Stroke*	1.0% (1/102)	0.0% (0/51)	2.6% (1/38)	0.0% (0/27)
Volume overload	2.0% (2/102)	0.0% (0/51)	5.3% (2/38)	0.0% (0/27)
Transient Ischemic Attack*	1.0% (1/102)	0.0% (0/51)	0.0% (0/38)	0.0% (0/27)

\* Event also classified as MAE in previous Tables.

[a] Pericardial effusions with tamponade physiology.

[b] Pericardial effusions (intervention or medical management).

In addition to those listed in Table 8, the following other events were reported in 5.9% (6/102) unique subjects in the all treated subjects EPI-Sense group: Acute kidney injury; abdominal hernia; jugular vein thrombosis; hyponatremia; multi-organ dysfunction; and nausea. Hemoptysis and urinary tract infection was reported in 3.9% (2/51) unique subjects in the Catheter Ablation group. For longstanding persistent AF subjects, other events were reported in 7.9% (3/38) unique subjects in the EPI-Sense group: acute kidney injury; abdominal hernia; and nausea. Urinary tract infection was reported in 3.7% (1/27) of subjects in the Catheter Ablation group.

### Secondary Effectiveness Results

The fixed-sequence procedure proposed, was prospectively specified in the SAP to evaluate the key secondary endpoints. Each of these tests were performed at the same two-sided significance level ( $\alpha=0.05$ ) in this predetermined order. Each endpoint was only tested if the prior endpoint was successful ( $p \leq 0.05$ ). This procedure maintained the Type I error rate as no further testing was performed once an endpoint in the sequence failed to show significance ( $p > 0.05$ ).

The fixed-sequential resulted in two statistically significant secondary endpoints:

- Proportion of subjects achieving  $\geq 90\%$  reduction from baseline AF burden and off Class I and III AADs, except for previously failed or intolerant Class I and III AADs with no increase in dosage at 12-months post-procedure.
- Proportion of subjects free of AF and off Class I and III AADs except for previously failed or intolerant Class I and III AADs with no increase in dosage following the 3-months blanking period through the 12-months post-procedure visit.

Analyses of these two statistically significant endpoints are presented in Tables 9.1 and 9.2. The other secondary effectiveness endpoints are descriptively summarized in Table 10.

The results for the persistent AF and longstanding persistent AF sub-populations are considered post-hoc and should be interpreted with caution since the confidence intervals are presented without adjustment for multiplicity.

### AF Burden Reduction of at Least 90% at 12-Months Compared to Baseline:

AF burden percentage was captured directly on the Zio patch report and was based on the total time the subject was in AF over the time the subject wore the Zio patch, after artifact removal. A  $\geq 90\%$  change from baseline is based on comparing the post-procedure AF burden percentage to the baseline AF burden percentage recorded on the Holter Monitor.

### All Treated Subjects

The proportion of subjects achieving at least 90% reduction in AF burden, absent of an increased dose or new Class I/III AADs, at 12-months compared to baseline was 80% (60/75) [95% CI: 70.9%, 89.1%] in the EPI-Sense treatment group, compared to 56.8% (25/44) [95% CI: 42.2%, 71.5%] in the Catheter Ablation group. The success rate difference of 23.2% [95% CI: 6.0%, 40.4%] is statistically significant (Chi-Squared  $p$ -value = 0.0069) in favor of the EPI-Sense treatment group.

The superiority of the EPI-Sense group over the Catheter Ablation group in achieving at least 90% reduction in AF burden at 12-months relative to baseline, absent of an increased dose or new Class I/III AADs, was achieved based on the ITT analysis. These

results were supported by the mITT (produced identical results as the ITT population) and PP population analyses.

### Persistent AF Subjects

The proportion of subjects achieving at least 90% reduction in AF burden, absent of an increased dose or new Class I/III AADs, at 12-months compared to baseline was 81.1% (30/37) [95% CI: 64.8%, 92.0%] subjects in the Epi-Sense treatment group compared to 72.2% (13/18) [95% CI: 46.5%, 90.3%] subjects in the Catheter Ablation group. The success rate difference was 8.9%.

### Longstanding Persistent AF Subjects

The proportion of subjects achieving at least 90% reduction in AF burden, absent of an increased dose or new Class I/III AADs, at 12-months compared to baseline was 78.9% (30/38) [95% CI: 66.0%, 91.9%] in the Epi-Sense treatment group, compared to 46.2% (12/26) [95% CI: 27.0%, 65.3%] in the Catheter Ablation group. The success rate difference was 32.8% [95% CI: 9.7%, 55.9%] in favor of Epi-Sense.

### AF Freedom Through 12-Months, Absent Class I/III AADs:

### All Treated Subjects

The proportion of subjects achieving AF freedom through 12-Months, absent of an increased dose or new Class I/III AADs was 70.6% (72/102) [95% CI: 61.7%, 79.4%] in

the Epi-Sense treatment group, compared to 51.0% (26/51) [95% CI: 37.3%, 64.7%] in the Catheter Ablation group. The difference in success rate of 19.6% [95% CI: 3.3%, 35.9%] is statistically significant (Chi-Squared p-value = 0.0172) in favor of the Epi-Sense treatment group. The superiority of the Epi-Sense group over the Catheter Ablation group in achieving at AF freedom through 12-months, absent of an increased dose or new Class I/III AADs, was achieved based on the ITT analysis. These results were supported by the mITT and PP population analyses.

### Persistent AF Subjects

The proportion of subjects achieving AF freedom through 12-Months, absent of an increased dose or new Class I/III AADs was 70.3% (45/64) [95% CI: 59.1%, 81.5%] in the Epi-Sense treatment group, compared to 66.7% (16/24) [95% CI: 47.8%, 85.5%] in the Catheter Ablation group. The difference in success rate was 3.6%.

### Longstanding Persistent AF Subjects

The proportion of subjects achieving AF freedom through 12-Months, absent of an increased dose or new Class I/III AADs was 71.1% (27/38) [95% CI: 56.6%, 85.5%] in the Epi-Sense treatment group, compared to 37.0% (10/27) [95% CI: 18.8%, 55.3%] in the Catheter Ablation group. The difference in success rate was 34.0% [95% CI: 10.8%, 57.3%] in favor of Epi-Sense.

**Table 9.1: Secondary Effectiveness Endpoints (Burden Reduction and Freedom from AF) – All Treated Subjects**

All Treated Subjects (N = 153)			
Secondary Effectiveness Endpoint	Epi-Sense (N = 102)	Catheter Ablation (N = 51)	p-value[b]
Achieved ≥90% Burden Reduction at 12 Months, without New/Increased Class I/III AADs: 95% Confidence Interval [a]	80.0% (60/75) 70.9 – 89.1%	56.8% (25/44) 42.2 – 71.5%	0.0069*
AF Free at 12 Months, without New/Increased Class I/III AADs: 95% Confidence Interval [a]	70.6% (72/102) 61.7 – 79.4%	51.0% (26/51) 37.3 – 64.7%	0.0172*

\*P-values that are statistically significant based on the fixed sequential testing specified in the SAP.

[a] Confidence intervals based on Wald asymptotic or Clopper-Pearson (Exact) method.

[b] Difference in change from baseline between treatment arms evaluated using an ANCOVA model with treatment arm and baseline score as covariates. Difference in percent of binary endpoints between treatment arms evaluated using Chi-Squared or Fisher's Exact test.

**Table 9.2: Secondary Effectiveness Endpoints (Burden Reduction and Freedom from AF) by AF type (Post-Hoc)**

Persistent and Longstanding Persistent AF Sub-Populations

Secondary Effectiveness Endpoints	Persistent AF Subjects (N = 88)		Longstanding Persistent AF Subjects (N = 65)	
	Epi-Sense (N = 64)	Catheter Ablation (N = 24)	Epi-Sense (N = 38)	Catheter Ablation (N = 27)
Achieved ≥90% Burden Reduction at 12 Months, without New/Increased Class I/III AADs: 95% Confidence Interval [a]	81.1% (30/37) 64.8 – 92.0%	72.2% (13/18) 46.5 – 90.3%	78.9% (30/38) 66.0 – 91.9%	46.2% (12/26) 27.0 – 65.3%
AF Free at 12 Months, without New/Increased Class I/III AADs: 95% Confidence Interval [a]	70.3% (45/64) 59.1 – 81.5%	66.7% (16/24) 47.8 – 85.5%	71.1% (27/38) 56.6 – 85.5%	37.0% (10/27) 18.8 – 55.3%

Note: Refer to footnotes on Table 9.1. Confidence intervals are not adjusted for multiplicity.




**Table 10: Additional Effectiveness Endpoints (All Treated Subjects)**

All Treated Subjects (N = 153)		
	Epi-Sense (N = 102)	Catheter Ablation (N = 51)
Achieved ≥90% Burden Reduction at 12 Months, Regardless of AADs: n (%)	96.0% (72/75)	88.6% (39/44)
AF Free at 12 Months, Regardless of AADs: n (%)	81.4% (83/102)	62.7% (32/51)
Change in AFSS Composite Score at 12 Months: n, Mean ± SD	60, -11.7 ± 7.71	37, -10.3 ± 7.16
Change in SF-36 Physical Health Composite Score at 12 Months: n, Mean ± SD	97, 7.3 ± 10.67	50, 5.7 ± 10.49
Change in SF-36 Mental Health Composite Score at 12 Months: n, Mean ± SD	97, 5.7 ± 10.51	50, 7.7 ± 12.78
Change in 6-Minute Walk Score at 12 Months: n, Mean ± SD	94, 9.2 ± 120.59	48, -12.4 ± 190.09
Change in LVEF at 6 Months, n, Mean ± SD	99, 3.5 ± 9.25	51, 1.9 ± 6.68
Change in Left Atrial Diameter at 6 Months: n, Mean ± SD	99, -0.1 ± 0.62	51, -0.2 ± 0.60
Burden of ≤ 12% at 12 Months, without New/Increased Class I/III AADs: n (%)	79.4% (77/97)	60.0% (30/50)
Burden of ≤ 12% at 12 Months, Regardless of AADs: n (%)	93.8% (91/97)	90.0% (45/50)
Achieved ≥90% Burden Reduction at 18 Months, Regardless of AADs: n (%)	88.9% (64/72)	88.1 (37/42)

### Subgroup Analysis Results

The primary effectiveness endpoint was summarized and analyzed by the following subgroups of interest as shown on Figure 3.

**FIGURE 3: FOREST PLOT OF PRIMARY EFFECTIVENESS ENDPOINTS FOR SUBGROUP ANALYSES (ALL TREATED SUBJECTS)**



Note: Confidence intervals are not adjusted for multiplicity.

## Quality of Life (SF-36 and AFSS) Results

Composite and scale scores for SF-36 and AFSS are summarized in Tables 11 and 12. These summary results are considered post-hoc and should be interpreted with caution. Subjects with missing data were excluded from the analyses.

**Table 11: Post-Hoc Quality of Life – SF-36**

	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
SF-36 Scores	Epi-Sense (N = 102) N, Mean ± SD	Catheter Ablation (N = 51) N, Mean ± SD	Epi-Sense (N = 38) N, Mean ± SD	Catheter Ablation (N = 27) N, Mean ± SD
<b>Physical Component Score</b>	97, 7.3 ± 10.67	50, 5.7 ± 10.49	38, 7.9 ± 9.27	27, 3.0 ± 10.40
Physical Functioning	97, 17.6 ± 27.30	50, 17.1 ± 27.41	38, 19.9 ± 26.72	27, 14.1 ± 27.56
Role Physical	97, 26.1 ± 31.50	50, 26.4 ± 31.27	38, 28.0 ± 28.43	27, 19.7 ± 31.62
Bodily Pain	97, 5.5 ± 25.08	50, 4.3 ± 21.28	38, 8.7 ± 20.68	27, 0.8 ± 23.65
General Health	97, 13.1 ± 9.36	50, 9.6 ± 22.92	38, 11.4 ± 18.50	27, 2.3 ± 22.75
<b>Mental Component Score</b>	97, 5.7 ± 10.51	50, 7.7 ± 12.78	38, 5.6 ± 13.49	27, 6.5 ± 14.61
Vitality	97, 21.8 ± 25.60	50, 19.4 ± 28.86	38, 19.1 ± 28.02	27, 12.0 ± 28.90
Social Functioning Score	97, 16.5 ± 27.04	50, 17.8 ± 33.22	38, 18.8 ± 29.03	27, 11.6 ± 36.35
Role Emotional	97, 10.4 ± 24.80	50, 17.5 ± 30.92	38, 11.8 ± 29.55	27, 16.0 ± 33.96
Mental Health	97, 8.6 ± 17.50	50, 10.9 ± 18.29	38, 9.1 ± 22.75	27, 10.6 ± 19.43

Note: SF-36 values range from 0 to 100 and higher values represent better quality of life.

**Table 12: Post-Hoc Symptom Relief – AFSS**

	All Treated Subjects (N = 153)		Longstanding Persistent AF Subjects (N = 65)	
AFSS Scores	Epi-Sense (N = 102) N, Mean ± SD	Catheter Ablation (N = 51) N, Mean ± SD	Epi-Sense (N = 38) N, Mean ± SD	Catheter Ablation (N = 27) N, Mean ± SD
AFSS Composite Score [a]	60, -11.7 ± 7.71	37, -10.3 ± 7.16	23, -12.9 ± 7.79	22, -9.8 ± 7.93
AFSS Overall Symptom [b]	97, -10.1 ± 7.82	50, -9.2 ± 8.35	38, -9.8 ± 7.55	27, -8.0 ± 7.75
Overall Subject-Perceived Severity Score [c]	95, -1.1 ± 2.84	50, -0.8 ± 2.91	37, -1.0 ± 2.84	27, -0.1 ± 2.57
Global Well-Being [d]	96, 1.1 ± 1.97	50, 1.3 ± 2.45	38, 1.2 ± 2.02	27, 0.6 ± 2.15
Atrial Fibrillation Frequency [e]	69, 7.0 ± 3.71	40, 6.2 ± 3.91	25, 7.5 ± 3.58	23, 6.4 ± 3.91
Atrial Fibrillation Duration [f]	62, 3.5 ± 3.54	37, 3.3 ± 3.17	24, 3.9 ± 3.78	22, 3.0 ± 3.67

[a] Scores from 3 to 30 and higher values represent greater burden.

[b] Scored as 1 = less severe to 35 = more severe.

[c] Scored as 1 = not at all severe to 10 = extremely severe.



[d] Scored as 1 = worst possible life to 10 = best possible life.

[e] Scored as 1 = continuously to 11 = less than once a year.

[f] Scored as 1 = continuously to 8 = a few minutes.

## Symptom Relief Results

Symptom relief assessments based on the AFSS are presented in Figures 4.1 and 4.2 for the all treated and the longstanding persistent AF sub-population for the Epi-Sense subjects. These summary results are considered post-hoc and should be interpreted with caution. Subjects with missing data were excluded from the analyses.



### Additional Data Analysis

Additional analysis was performed based alternative HRS definitions of treatment success:

- Freedom from atrial arrhythmias from the 3-month blanking period through 12- and 18-months, after removal from antiarrhythmic drug therapy.
- Freedom from atrial arrhythmias from the 3-month blanking period through 12- and 18-months, regardless of antiarrhythmic drug therapy.

The results presented for all treated patients (N = 153) and the longstanding persistent AF sub-population are considered post-hoc and should be interpreted with caution since the confidence intervals are presented without adjustment for multiplicity. The confidence intervals calculated using the Wald asymptotic method and are presented only for descriptive purpose and are neither adjusted for multiplicity nor related to any prospectively defined hypothesis.

The summary of the analysis is provided in Tables 13.

**Table 13: Post-Hoc Additional Effectiveness Endpoints**

(Freedom from AF/AFL/AT Absent Class I/III AADs and Freedom from AF/AFL/AT Regardless of Class I/III AADs)

Effectiveness Endpoint	All Treated Subjects (N = 153)			Longstanding Persistent AF Subjects (N = 65)		
	Epi-Sense (N = 102)	Catheter Ablation (N = 51)	Treatment Difference 95% CI [c]	Epi-Sense (N = 38)	Catheter Ablation (N = 27)	Treatment Difference 95% CI [c]
<b>Effectiveness from 3-Months Post-Blanking Period through 12-Months</b>						
Freedom from Arrhythmia off AADs [a]	52.0% (53/102)	31.4 (16/51)	20.6% (4.6 – 362.6%)	52.6% (20/38)	25.9% (7/27)	26.7% 3.8 – 49.6%
Freedom from Arrhythmia Regardless of AADs [b]	74.5% (76/102)	58.8% (30/51)	15.7% (-0.25 – 31.6%)	73.7% (28/38)	44.4% (12/27)	29.2% 5.8 – 52.6%
<b>Effectiveness from 3-Months Post-Blanking Period through 18-Months</b>						
Freedom from Arrhythmia off AADs [a]	43.1% (44/102)	23.5% (12/51)	19.6% (4.5 – 34.7%)	47.4% (18/38)	22.2% (6/27)	25.2% 2.8 – 47.5%
Freedom from Arrhythmia Regardless of AADs [b]	63.7% (65/102)	47.1% (24/51)	16.7% (0.0 – 33.2%)	68.4% (26/38)	33.3% (9/27)	35.1% 12.0 – 58.2%

[a] Freedom from arrhythmia after removal of Class I or III antiarrhythmic drug therapy.

[b] Freedom from arrhythmia regardless of Class I or III antiarrhythmic drug therapy.

[c] Confidence intervals are not adjusted for multiplicity.


**Key Effectiveness Endpoints from 3-Months Blanking Period Through 18-Months**

The primary effectiveness endpoint and the key secondary effectiveness endpoints of burden reduction and freedom from AF were summarized from the 3-months blanking period through 18-months. The results are presented in Figures 5.1 and 5.2.

The 18-months effectiveness analyses for the all treated subjects, and the longstanding persistent AF sub-population are considered post-hoc and should be interpreted with caution since the confidence intervals are presented without adjustment for multiplicity.


For the “All Treated” population, missing arrhythmia endpoints data were imputed as treatment failures. Missing burden data were not imputed. For the longstanding persistent AF sub-population, there were no missing arrhythmia data. Missing burden data were not imputed for this sub-population.

**Figure 5.1: Key Effectiveness Endpoints from 3-Months Blanking Period Through 12- and 18-Months (All Treated Subjects)**



Note: Confidence intervals for the 18-months analyses are not adjusted for multiplicity.

**Figure 5.2: Post-Hoc Key Effectiveness Endpoints from 3-Months Blanking Period Through 12- and 18-Months (Longstanding Persistent AF Patients)**



Note: Confidence intervals are not adjusted for multiplicity.



## Included Endocardial Irrigated Catheters

The following endocardial irrigated catheters were used during the Converge study:

**Table 14: Endocardial Irrigated Catheters Used in the CONVERGE Study**

No	Description of Endocardial Irrigated Ablation Catheter	Manufacturer
1	CELSIUS® THERMOCOOL® Catheter	Biosense Webster, Inc
2	EZ STEER® THERMOCOOL® Catheter	Biosense Webster, Inc
3	FlexAbility™ Irrigated Ablation Catheter	Abbott Laboratories
4	IntellaNav™ Open-Irrigated Ablation Catheter	Boston Scientific Corporation
5	Safire BLU™ Duo Irrigated Ablation Catheter	Abbott Laboratories*
6	TactiCath™ Quartz Contact Force Ablation Catheter	Abbott Laboratories*
7	Therapy™ Cool Path™ Duo Irrigated Ablation Catheter	Abbott Laboratories*
8	Therapy™ Cool Path™ Irrigated Ablation Catheter	Abbott Laboratories*
9	THERMOCOOL® SF Catheter	Biosense Webster, Inc
10	THERMOCOOL® SF NAV Catheter	Biosense Webster, Inc
11	THERMOCOOL SMARTTOUCH® Catheter	Biosense Webster, Inc
12	THERMOCOOL SMARTTOUCH® SF Catheter	Biosense Webster, Inc

\*Abbott Laboratories (formerly, St. Jude Medical, Inc.)

## CONCLUSIONS

### Effectiveness Conclusions

The effectiveness outcomes of the CONVERGE study demonstrate that the hybrid convergent procedure with EPi-Sense® Guided Coagulation System is effective for the treatment of symptomatic drug refractory recurrent persistent atrial fibrillation. Freedom from AF/AT/AFL absent Class I and III AADs except for a previously failed or intolerant Class I or III AAD with no increase in dosage following the 3-month blanking period through the 12-months post procedure follow up visit was achieved in 65.7% (67/102) [95% CI: 56.5%, 74.9%] subjects in the EPi-Sense treatment group compared to 49.0% (25/51) [95% CI: 35.3%, 62.7%] subjects in the Catheter Ablation group. The observed success rate difference of 16.7% [95% CI: 0.1%, 33.2%] is statistically significant (Chi-Squared p-value = 0.0472).

Post-hoc subgroup analysis showed that the difference in the primary effectiveness endpoint success was driven primarily by the substantial treatment effect difference in the long-standing persistent AF sub-population. In patients with a history of continuous AF > one year, the primary effectiveness success rate difference was 28.8% (95% CI: 5.1%, 52.4%) through 12 months in favor of EPi-Sense. The effectiveness results in the longstanding persistent AF sub-population are consistent and clinically significant regardless of the duration of evaluation (i.e., 12- or 18-months).

### Safety Conclusions

The primary safety event rate was 7.84% (8/102) [95% UCL: 13.7%]. No deaths occurred within 30-days of the procedure and no AEFs or cardiac perforations were reported. The events reported included: pericardial effusions; excessive bleeding; phrenic nerve injury; TIA; and stroke. Almost all of these safety events resolved without sequelae. There were no deaths attributable to the EPi-Sense Guided Coagulation System or hybrid Convergent procedure.

The rate of pericardial effusion requiring percutaneous and/or surgical drainage was 5.9%. These events were delayed onset and likely represent inflammatory response to pericardiotomy and the pericardial ablation procedure with the device. They occurred 1-3 weeks post-ablation, and were treated successfully with timely recognition.

### Overall Conclusions

The totality of evidence from the randomized CONVERGE clinical trial and real-world clinical experience demonstrates there is a reasonable assurance of safety and effectiveness to support the use of the EPi-Sense device to treat patients presenting with symptomatic drug refractory longstanding persistent atrial fibrillation.

## GLOSSARY OF TERMS

<b>Electrocoagulation</b>	Surgical procedures in which high-frequency electric current is used to coagulate tissues.
<b>Coagulation Electrode</b>	The metal conductor in the coagulation device used to transmit radiofrequency energy to tissue.
<b>Sensing Electrodes</b>	Metal conductors between the coagulation electrode used to sense cardiac voltages from the heart.
<b>Indifferent, Dispersive Electrode</b>	Commonly referred to as the “return electrode” or “patient electrode” or “ground pad.” Large surface area indifferent ground used to complete the circuit of the electrical current. Usually placed on the patient’s back or thigh, the indifferent, dispersive electrode is connected to the generator at the Indifferent Connector.

## SYMBOLS

	Vacuum		Radiofrequency
	Open Circuit		IRRIG: Perfusion
	Equipotential		Watts
	Seconds		Ohms
	Time		Manufacturer
	Caution		Country and Date of Manufacture
	Catalog Number		Batch Code
	Model Number		Unique device identifier
	Prescription Use Only		Use-By Date
	Do Not Resterilize		Do Not Re-Use
	Do Not Use if Package is Damaged		Single sterile barrier system with protective packaging inside
	Sterilized using irradiation		Single sterile barrier system with protective packaging outside
	Not made with Natural Rubber Latex		Follow instructions for use
	Waste Electrical and Electronic Equipment		Does not contain Phthalates
	Contains hazardous substances		Defibrillation Proof Type CF Applied Part
	Non-pyrogenic		Non-ionizing Radiation
	Caution: Electrical Shock Hazard		Footswitch Connection
 131°F (55°C) -20°F (-29°C) Transit/Storage Temperature limit			Indifferent, Dispersive Electrode
		 30% - 85% Transit/Storage Humidity limit	

## LIMITED WARRANTY

AtriCure warrants that reasonable care has been used in the design and manufacture of this instrument. This warranty is in lieu of and excludes all other warranties not expressly set forth herein, whether expressed or implied by operation of law or otherwise, including, but not limited to, any implied warranties of merchantability or fitness for a particular use. AtriCure's sole obligation under this warranty is limited to the repair or replacement of this instrument. AtriCure neither assumes, nor authorizes any other person to assume for it, any other or additional liability or responsibility in connection with this instrument.

Handling, storage, cleaning and sterilization of this instrument as well as other factors relating to the patient, diagnosis, treatment, surgical procedures, and other matters beyond AtriCure's control directly affect the instrument and the result obtained from its use. AtriCure assumes no liability with respect to instruments deliberately mis-used or those reused, reprocessed or re-sterilized and makes no warranties expressed or implied, including but not limited to merchantability or fitness for intended use, with respect to such mis-used or reused instruments. AtriCure shall not be liable for any incidental or consequential loss, damage, or expense directly or indirectly arising from the deliberate mis-use or re-use of this instrument.

## DISCLAIMER

Users assume responsibility for approving the acceptable condition of this product before it is used, and for ensuring that the product is only used in the manner described in these instructions for use, including, but not limited to, ensuring that the product is not re-used.

Under no circumstances will AtriCure, Inc. be responsible for any incidental, special or consequential loss, damage, or expense, which is the result of the deliberate misuse or re-use of this product, including any loss, damage, or expense which is related to personal injury or damage to property.

## DISPOSAL:

After use this device should be treated as medical waste and disposed of following hospital protocol.

## RETURN OF USED PRODUCT:

For any reason this product must be returned to AtriCure, Inc., a return goods authorization (RGA) number is required from AtriCure, Inc., prior to shipping. If the product has been in contact with blood or body fluids, it must be thoroughly cleaned and disinfected before packing. It should be shipped in either the original carton or an equivalent carton, to prevent damage during shipment; and it should be properly labeled with an RGA number and an indication of the biohazardous nature of the contents of shipment. Instructions for cleaning and materials, including appropriate shipping containers, proper labeling, and an RGA number may be obtained from AtriCure, Inc.



AtriCure Inc.  
 7555 Innovation Way  
 Mason, Ohio 45040 USA  
 +1 866 349 2342  
 +1 513 755 4100

***This Page Intentionally Left Blank***